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ABSTRACT 
Bile acids (BAs) serve multiple functions.  BA feeding has been used to study 
BA signaling and toxicity in vivo.  However, the concentration of BAs in the feed that 
is non-hepatotoxic is not well defined in mice.  Therefore, the purpose of my first 
study in my dissertation was to determine the non-hepatotoxic and hepatotoxic 
concentrations of five BAs in mouse feed, as well as the effect of feeding mice 
individual BAs on BA concentrations and BA composition in liver.  Mice were fed five 
individual BAs, cholic acid (CA), chenodeoxycholic acid (CDCA), deoxycholic acid 
(DCA), lithocholic acid (LCA), and ursodeoxycholic acid (UDCA) at 0.01, 0.03, 0.1, 
0.3, 1.0, or 3.0% in their diets for 7 days.  The data showed: 1) LCA, DCA, and 
CDCA at 1.0% in the diets were lethal, whereas CA at 1% and UDCA at 3.0% were 
not lethal.  2) LCA produced hepatotoxicity at 0.03%, indicated by increases in 
serum ALT and serum BA concentration, as did DCA at 0.1%, and CDCA and CA at 
0.3% in the diet.  UDCA at 0.3% in the diet might be hepatotoxic because the serum 
BA concentration was increased but the serum ALT did not increase.  3) Feeding 
BAs (CA, CDCA, DCA, or LCA) at hepatotoxic doses did not alter the total BA 
concentration in liver; however it altered liver BA composition, including increases in 
the percentage of the fed-BAs, and decreases in the percentage of MCAs 
(muricholic acids).  In conclusion, it appears that an imbalance in BA composition in 
liver can contribute to BA hepatotoxicity.  In addition, to study the physiological or 
pharmacological functions of each BA, non-hepatotoxic concentrations of BAs in the 
feed should be used.  Our data show that to avoid hepatotoxicity, CA and CDCA 
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should be at 0.1% or lower, DCA at 0.03% or lower, and LCA at 0.01% or lower in 
the diet.     
BAs can regulate their own biosynthesis and transport at the transcriptional 
level via activation of FXR.  My first study has shown that feeding mice BAs at either 
non-hepatotoxic or hepatotoxic doses did not increase the total liver BA 
concentration, suggesting adaptation in the expression of genes involved in BA 
biosynthesis and transport.  Thus, the purpose of the second study in my 
dissertation was to investigate the expression of genes involved in BA homeostasis 
and the possible roles of hepatic and ileal FXR signaling in regulating these genes to 
maintain total BA concentrations in the livers of mice fed different doses of BAs.  
Mice were fed five individual BAs, CA, CDCA, DCA, LCA, and UDCA, at various 
concentrations (0.01, 0.03, 0.1, 0.3, 1.0, or 3.0%) in the diet for one week.  
Messenger RNAs of genes involved in BA homeostasis were quantified using 
QuantiGene Plex assays.  FXR in liver was activated by all the BAs and at all doses, 
indicated by induction of SHP mRNA in the livers.  Correspondingly, the Cyp7a1 
mRNA was reduced by all the BAs and at all doses.  In contrast, the activation of the 
FXR-Fgf15 signaling pathway in the ileum is BA species dependent: the 12-OH BAs 
(CA and DCA) increased Fgf15 mRNA expression at all doses, whereas, the non-
12-OH BAs (CDCA and LCA) increased Fgf15 mRNA expression only at high doses.  
Inversely to the activation pattern of FXR-Fgf15 signaling, Cyp8b1 was suppressed 
by the 12-OH BAs at all doses, and by the non-12-OH BAs at high-hepatotoxic 
doses.  BAs had less of an effect on BA transporter expression; only high-
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hepatotoxic doses of BAs decreased Ntcp.  In addition, all doses of the BAs induced 
the mRNA of Abcg5/g8, whereas, only at high-hepatotoxic doses did all the BAs 
increased Mdr2 mRNA expression.  
In summary, these results indicated that the hepatic FXR-SHP signaling 
pathway in the liver appears to mediate the suppression of Cyp7a1 by BAs, whereas, 
the FXR-Fgf15 signaling pathway in the ileum appears to mediate the suppression of 
Cyp8b1 by all doses of the 12-OH BAs and by the high-hepatotoxic doses of the 
non-12-OH BAs.  The suppression of Cyp7a1 appears to be sufficient to maintain 
the total liver BA concentration when mice are fed BAs at non-hepatotoxic doses,  
whereas, the suppression of the BA uptake transporter Ntcp, in addition to the 
suppression of Cyp7a1, is needed to maintain the total BA concentration in livers of 
mice fed high-hepatotoxic doses of BAs.  The suppression of Cyp8b1 results in an 
imbalanced BA composition which may result in hepatotoxicity.  Moreover, the 
increased expression of Abcg5/g8 and Mdr2 may result in increased secretion of 
cholesterol and phospholipids that contributes to the formation of mixed micelles 
with BAs, and limits the hepatotoxicity of the fed-BAs. 
The third study in my dissertation investigated the effects of BA sequestration 
by resin on the BA-receptor mediated signaling pathways.  Mice were fed 2% resin 
in their diets for one week.  The BAs in both serum and livers, as well as the mRNA 
involved in BA homeostasis were quantified.  The data demonstrated that the resin 
tended to increase the total serum BA concentration, but significantly decreased β-
MCA concentration 50% and increased CA and T-CA in serum.  As expected, 
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feeding mice the resin decreased the total liver BA concentration 80%, which was 
due to an almost complete depletion of α-, β-, and ω-MCAs, as well as their taurine 
conjugates, and less of a decrease in most of the other BAs.  In addition, the resin 
also altered the liver BA composition, featured by an increase in the percentage of 
the total CA and the secondary BA DCA.  The mRNA of the BA-biosynthesis 
enzymes, Cyp7a1 and Cyp8b1, was increased 180 and 100% respectively.  
However, mRNA of the FXR target gene SHP in liver was not decreased.  In 
contrast, the ileal Fgf15 mRNA expression was significantly decreased.  Feeding the 
resin did not alter the BA uptake transporters on the sinusoidal membrane nor did it 
alter the efflux transporters on the canalicular membrane. In contrast, the efflux 
transporters on the sinusoidal membrane of hepatocytes, Mrp 3 and 4, were 
increased following resin treatment 22 and 150% respectively.  In ileum, feeding the 
resin increased the uptake transporter, Asbt by 66%.  Collectively, the data suggest 
that increased expression of Cyp7a1 and Cyp8b1 in mouse liver by resin 
administered through the diet appears to be due to a decrease in the ileal Fgf15 
signaling pathway, rather than due to a decrease in hepatic FXR signaling.  
In conclusion, my dissertation demonstrates that imbalanced BA composition 
without increases in total liver BA concentrations can cause hepatotoxicity.  The 
doses used by most researchers in studying BA functions are hepatotoxic.  To study 
physiological functions of BAs, non-hepatotoxic doses of individual BAs are 
recommended: 0.1% or lower in the diets for CA, CDCA, and UDCA, 0.03% for DCA, 
and 0.01% or lower for LCA.  In addition, the altered liver BA composition after non-
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hepatotoxic doses of BA-feeding are able to trigger BA receptor signaling pathways 
(including the hepatic FXR-SHP and the ileal FXR-Fgf15 mediated signaling 
pathways) which coordinately regulate the biosynthesis enzymes Cyp7a1 and 
Cyp8b1 to maintain the total liver BAs and to somewhat restore liver BA composition 
which is disturbed by administration of the exogenous BAs.  The completely 
disturbed liver BA composition after hepatotoxic-doses of BA-feeding not only 
suppresses both Cyp7a1 and Cyp8b1, but also decreases the expression of Ntcp, 
which may contribute to the maintenance of the liver total  BA concentration as well.  
Moreover, the decrease in BA concentration after resin-feeding interrupts the ileal 
FXR-Fgf15 signaling resulting in increased expression of Cyp7a1 and Cyp8b1.   
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INTRODUCTION 
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1.1 BA Biochemistry  
1.1.1  BA Structures 
The composition of BAs in bile varies among species.  In humans and rats, 
the primary BAs are cholic acid (CA) and chenodeoxycholic acid (CDCA), whereas 
in mice, CA and muricholic acids (MCAs, including α-, and β-MCA) are the major 
primary BAs in bile; in bears, ursodeoxycholic acid (UDCA) is the major BA (Elias, 
1999).  In humans, the primary BAs can be further metabolized by intestinal bacteria 
producing the secondary BAs: deoxycholic acid (DCA) from CA, and lithocholic acid 
(LCA) from CDCA.  In rodents, the primary BAs α-, and β-MCA can be further 
metabolized into ω-MCA.  The primary BAs are relatively more water soluble, and 
less toxic than the secondary BAs (Salvioli et al., 1982; Botham and Boyd, 1983; 
Lida et al., 1989; Miki et al., 1993; Eyssen et al., 1999). 
The basic structure of BAs is characterized by the steroid nucleus of four 
fused hydrocarbon rings and a hydroxyl group at the 3-carbon position of the steroid 
nucleus (Fig 1-1).  Various BAs differ in the presence of additional hydroxyl groups 
at the 6-, 7- and/or 12-carbon positions, and the orientation of hydroxyl groups on 
the steroid nucleus.  CA has both a 7α-hydroxyl group and a 12-hydroxyl group; 
whereas CDCA has only a 7α-hydroxyl group in addition to the 3α-OH group. DCA 
has one additional hydroxyl group at the 12-carbon position, whereas there are no 
hydroxyl groups at either the 7- or 12-carbon position of LCA. UDCA, an isomer of 
CDCA, has a β-hydroxyl group instead of α-hydroxyl group at the 7-carbon position 
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(Fig 1-1).  In rodents, the primary BA, in addition to CA is muricholic acid (MCA) 
which has hydroxyl groups in the 6 and 7 carbon position (Radominska et al., 1993; 
Fujino et al., 2004; Thomas et al., 2008) . 
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BAs R1 R2 R3 
Cholic Acid (CA) H OH(α) OH 
Chenodeoxycholic Acid (CDCA) H OH(α) H 
Deoxycholic Acid (DCA) H H OH 
Hyodeoxycholic Acid (HDCA) OH (α) H H 
Lithocholic Acid (LCA) H H H 
Muri-Cholic Acid (MCA) OH  OH H 
α Muri-Cholic Acid (αMCA) OH (β) OH (α) H 
β Muri-Cholic Acid (βMCA) OH (β) OH (β) H 
ω Muri-Cholic Acid (ωMCA) OH (α) OH (β) H 
Murideoxycholic Acid (MDCA) OH (β) H H 
Ursodeoxycholic Acid (UDCA) H OH(β) H 
 
Fig 1-1.  Structure of the most common BAs (Eyssen et al., 1999; Fujino et al., 2004; 
Thomas et al., 2008) 
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1.1.2.    Biosynthesis of BAs 
BAs are natural end products of cholesterol catabolism. Various cytochrome-
P450 enzymes are involved in the conversion of cholesterol to BAs.  There are two 
major pathways involved in BA biosynthesis: the classic (neutral) pathway initiated 
by Cyp7a1, and the alternative (acidic) pathway initiated by Cyp27a1 (Norlin and 
Wikvall, 2007; Thomas et al., 2008). 
Classic Pathway for BA Biosynthesis: Cholesterol 7α-hydroxylase 
Mediated Pathway  
The classic BA biosynthesis pathway is also called the neutral pathway.  BA 
synthesis through this pathway occurs uniquely in liver because the rate-limiting 
enzyme, cholesterol 7α-hydroxylase (Cyp7a1), is a liver-specific enzyme.  In this 
classic pathway, the steroid nucleus is first modified by cytochrome-P450 enzymes, 
followed by the shortening and modification of the side chain.  The first step of this 
pathway is the conversion of cholesterol into 7α-hydroxyl cholesterol, which is 
catalyzed by Cyp7a1.   The intermediate product 7α-hydroxyl cholesterol can be 
hydroxylated by the Cyp8b1 enzyme which adds an additional hydroxyl group to the 
12-carbon position, leading to production of CA.  Without Cyp8b1, the intermediates 
will be used to produce CDCA (Fig 1.2) (Norlin and Wikvall, 2007).   
Primary BAs are usually conjugated with amino acids, namely glycine and 
taurine, to produce either glycine or taurine conjugated BAs.  These conjugated BAs 
are actively secreted into bile.  Conjugated BAs are the major form of BAs excreted 
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by liver.  In the intestine, bacteria convert the primary BAs into secondary BAs by 
deconjugation and dehydroxylation at the 7-position to produce DCA from CA, and 
LCA from CDCA.  LCA can be further hydroxylated at the 6 carbon position to 
produce either hyodeoxycholic acid (HDCA) or murideoxycholic acid (MDCA).  
HDCA can also be formed by 7-dehydroxylation from MCA . The secondary BAs are 
more hydrophobic than their precursor BAs.  LCA is the least water-soluble BA, and 
very little is reabsorbed and returned to the liver through the portal vein.  Most of the 
other BAs, including CA, CDCA, and DCA are reabsorbed and recycled.  This 
process is referred to as the enterohepatic circulation.  In humans, the major 
products of the classic pathway are similar amounts of CA and CDCA.  
Alternative (Acidic) Pathway: Sterol 27-hydroxylase Mediated Pathway 
The alternative pathway of BA-biosynthesis is initiated in the mitochondria, 
either in the liver or in peripheral tissues.  Cholesterol in the cytosol needs to be 
transported into the mitochondria by steroid-acute-response protein (StAR). 
Transport of cholesterol from cytosol into mitochondria is the rate-limiting step in the 
alternative pathway of BA biosynthesis.  After cholesterol enters the mitochondria, 
Cyp27a1 catalyzes the hydroxylation of the side chain of cholesterol, which 
produces oxysterols.  These oxysterols can be transferred from peripheral tissues to 
hepatocytes, where hydroxylation occurs at position 7 of the steroid nucleus by 
Cyp7b1 and at position 12 by Cyp8b1.   The major product of the alternative 
pathway is CDCA.  The CDCA produced in this pathway then undergoes further 
biotransformation, as in the neutral pathway, namely conjugation with glycine and 
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taurine, entry into enterohepatic circulation, conversion into secondary BAs by 
bacteria in the intestine, reabsorption and return to the liver (Norlin and Wikvall, 
2007).   
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Fig 1-2.  Major BA biosynthesis pathways: The classic (red arrows) and the alternative 
pathways (blue arrows).  Cyp7a1, cholesterol 7α-hydroxylase;  Cyp8b1, sterol 12α –
hydrosylase;  Cyp27a1, sterol 27-hydroxylase;  Cyp7b1,  oxysterol 7α-hydroxylase (Thomas 
et al., 2008). 
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Other Pathways 
Cholesterol 25-hydroxylase and cholesterol 24-hydroxylase mediated 
pathways 
In the classic pathway, cholesterol is initially converted in the liver to 7α-
hydroxycholesterol by the rate-limiting enzyme, cholesterol 7α-hydroxylase 
(Cyp7a1). In the alternative pathway, cholesterol is first converted to oxysterols.  In 
liver and extrahepatic tissues (e.g. macrophages), this involves sterol 27-
hydroxylase (Cyp27a1) or cholesterol 25-hydroxylase (CH25H), whereas in brain, 
this step is exclusively catalyzed by cholesterol 24-hydroxylase (Cyp46). The 
oxysterols are then 7β-hydroxylated by oxysterol 7β-hydroxylases (Cyp7b1 and 
Cyp39a1) (Fuchs, 2003; Norlin and Wikvall, 2007) 
In extrahepatic and intrahepatic tissues, only a very small fraction of 
cholesterol is converted into 25-hydroxycholesterol as a result of the very low levels 
of cholesterol 25-hydroxylase.  A brain-specific Cyp enzyme, Cyp46, converts 
cholesterol into 24-hydroxycholesterol.  These two oxysterols are then transferred 
into hepatocytes, where 25-hydroxycholesterol is catalyzed by Cyp7B1, whereas 24-
hydroxycholesterol is catalyzed by Cyp39A1, producing 7α-hydroxylated oxysterols, 
which are further metabolized by Cyp27A1 to CA or CDCA (Fuchs, 2003; Norlin and 
Wikvall, 2007). 
The contribution of BA products by these pathways differs among various 
species.  In adult humans, the classic pathway contributes about 80% of CA and 
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CDCA, whereas the alternative pathway contributes less than 20% of BAs to the BA 
pool.  It has been proposed that less than 5-16% of the total BAs are derived from 
the cholesterol 25-hydroxylase pathway.  The cholesterol 24-hydroxylase pathway 
contributes least to the BA pool.  In human infants, the percentage of CDCA in the 
gallbladder is very high.  In addition, the Cyp7b1 enzyme is critical for fetuses to 
survive.  The data suggest that a large contribution is made by the cholesterol 27-
hydroxylase pathway in fetuses.  In rats and mice, the alternative pathway of BA 
synthesis contributes much more than 50% of the total BAs (Fuchs, 2003).  
Conjugation of BAs 
Newly synthesized unconjugated BAs or deconjugated BAs from the 
enterohepatic circulation are extensively conjugated with either glycine or taurine in 
the liver.  Two enzymes are critical in the conjugation process: bile acid-CoA ligase 
(BAL) catalyzes the formation of BA-CoA, and BA-CoA:amino acid N-
acyltransferase (BAT) amidates BA-CoA with the amino acid glycine or taurine 
(Thomas et al., 2008).  
BAT genes have been cloned from mouse (Falany et al., 1997), rat (Furutani 
et al., 1995), and human (Falany et al., 1994). The human BAT protein can 
conjugate BAs with both taurine and glycine  (Falany et al., 1994), but the mouse 
BAT protein only catalyzes the conjugation of BAs with taurine  (Falany et al., 1997). 
1.2.   Physiological Functions of BAs 
1.2.1. Bile Formation and Enterohepatic Circulation of BAs   
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Formation of bile is an important function of liver.  Bile is mainly composed of 
BAs, bilirubin, cholesterol, phospholipid, electrolytes, water, and various metabolites.  
Bile flow is driven by two forces: The active transport of BAs by hepatocytes into bile 
canaliculi mediates the BA dependent canalicular bile flow (Wheeler, 1972), 
whereas the active transport of the organic solute glutathione (GSH), and inorganic 
electrolyte bicarbonate (HCO3-) by hepatocytes or cholangiocytes mediates the BA 
independent bile flow.  Active transport of BAs and other organic solutes generate 
osmotic gradients that facilitate the entrance of water and electrolytes into 
canalicular bile.  Canalicular bile accounts for 75% of daily bile formation.  Bile 
formed in the ductules and ducts, so-called ductualar bile, accounts for 25% of daily 
bile secretion (Ballatori and Truong, 1992; Tietz et al., 2003).   
Canalicular bile formation depends on active hepatocellular transport systems. 
The hepatocytes are polarized epithelia with transporter proteins that actively take 
up or efflux bile components.  Canalicular bile secretion is facilitated by active 
transport of BAs and other organic solutes via ATP-binding cassette (ABC) 
transporters.  The bile salt export pump Bsep actively transfer glycine or taurine 
conjugated monovalent BAs, including conjugated CA, CDCA, DCA, and UDCA, 
from hepatocytes into Canaliculi (Gerloff et al., 1998).  Multidrug resistance 
associated protein Mrp2 actively pumps the divalent BAs, such as sulfated LCA, into 
bile (Muller and Jansen, 1997).  In addition, Mrp2 also actively transports reduced 
glutathione (GSH) (Trauner et al., 1998) and a variety of other anionic compounds 
(such as bilirubin glucuronide) conjugated with glutathione, glucuronates, or sulfate 
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into bile (Dubuisson et al., 1996; Cui et al., 1999; Keppler and Konig, 2000).   The 
multidrug resistance 1 (Mdr1) mediates the canalicular secretion of cationic 
compounds, whereas, the Mdr2 mediates the excretion of phospholipid by 
transolcating the phospholipid from the inner to the outer leaflet of the membrane 
(Smit et al., 1993; Elferink et al., 1997).  Abcg5/g8 mediates the biliary excretion of 
cholesterol.  In addition, there are also efflux pumps located at the basolateral 
membrane of hepatocytes.  Mrp3, Mrp4, and the heteromeric organic solute 
transporter Ostα/β pump BAs and other solutes from hepatocytes back into the 
systemic blood (Kullak-Ublick et al., 2004) .   
BAs secreted into bile undergo enterohepatic circulation (EHC).  EHC of BAs 
is important in maintaining the homeostasis of BAs.  Two main processes are 
involved in the EHC: Liver secretion and intestinal absorption of BAs.  After BAs are 
synthesized in liver, they are transported into bile canaliculi via various efflux 
transporters: Bsep and Mrps.  BAs in the canaliculi enter and are stored in the 
gallbladder.  Upon each meal, the gallbladder releases BAs into the intestine to 
emulsify dietary lipids and cholesterol to facilitate their absorption.   
In the ileum, about 95% of the BAs are reabsorbed. The enterocytes take up 
BAs via the apical sodium dependent BA transporter (Asbt).  Inside the enterocytes, 
the cytosolic ileal BA binding protein (Ibabp) mediates the transcelluar movement of 
BAs to the basolateral membrane of the enterocytes.  The organic solute 
transporters (Ostα/β) pump BAs into the portal vein.  BAs in the portal vein are 
transported back into the hepatocytes via two types of uptake transporters on the 
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sinusoidal membrane of hepatocytes: Na+/taurocholate cotransporting polypeptide 
(Ntcp) and organic anion transport polypeptides (Oatps) (Alrefai and Gill, 2007).  
These BAs together with newly synthesized BAs then enter the next EHC cycle.  
1.2.2.   BA Regulation of Their Own Homeostasis  
It is very important to maintain a balance between BA biosynthesis, transport 
and metabolism, because every aspect of BA homeostasis can affect various 
important physiological processes (Chawla et al., 2000; Houten et al., 2006).  The 
genes involved in BA biosynthesis are tightly regulated.  Since the discovery that 
nuclear receptors are involved in the regulation of BA biosynthesis pathways about 
ten years ago, there has been a marked increase in research in regulation of BA 
biosynthesis and transport (Grober et al., 1999; Downes et al., 2003) 
BA Regulation of Their Biosynthesis 
The most intensively studied gene in BA biosynthetic pathways is Cyp7a1 
(Chiang and Stroup, 1994; Goodwin et al., 2000; Chiang et al., 2001; Kim et al., 
2007), which is the rate limiting enzyme in the classic pathway of BA biosynthesis, 
followed by Cyp8b1 (Andersson et al., 1999; Lu et al., 2000; Sinal et al., 2000; 
Zhang and Chiang, 2001; Yang et al., 2002; Jahan and Chiang, 2005), which is the 
key enzyme determining the ratio of CA to CDCA in the BA pool, and Cyp27a1 
(Araya et al., 2003; Chen and Chiang, 2003; Quinn et al., 2005), which is the key 
enzyme in oxysterol synthesis outside the liver.  It has been known for a long time 
that Cyp7a1 is precisely regulated in the body.  Cholesterol and its metabolites (e.g. 
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oxysterols) can up-regulate Cyp7a1 (Doerner et al., 1995; Lehmann et al., 1997; 
Menke et al., 2002; Xu et al., 2004), whereas BAs down-regulate Cyp7a1 (Pandak 
et al., 1994; Gupta et al., 2001; Xu et al., 2003).  However, the underlying 
mechanisms by which Cyp7a1 is regulated were not well understood until the 
discovery that nuclear receptors are involved in the regulation of BA metabolism.  
Introduction to Nuclear Receptors  
Nuclear receptors comprise one of the superfamilies of transcription factors 
that regulate gene expression in a ligand dependent manner.  According to their 
ligands, the nuclear receptor superfamily is divided into three groups (Mangelsdorf 
et al., 1995).  The first group is the endocrine receptor subfamily whose ligands have 
high affinity to the corresponding receptors, for example, estrogen to the estrogen 
receptor.  The second group is called the adopted-orphan-nuclear receptors whose 
ligands have low affinity to their corresponding receptors and are usually dietary 
lipids, for example, BAs are the ligands of farnesoid X receptor (FXR).  The third 
group contains the so called orphan-nuclear receptors with ligands not yet identified, 
including SHP, LRH-1, HNF-4, etc.  
Even though the nuclear receptor transcription factors regulate genes that 
span across a broad range, from development to physiology and homeostasis, they 
have similar modular structures.  Generally five domains can be identified according 
to the conservation of DNA sequence and function of the regions: the N-terminal 
domain (A/B region), the DNA binding domain (DBD, C region), hinge domain (D 
region), ligand binding domain (LBD, E region), and C terminal domain (F region). 
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Among all these domains, the DBD is the most conserved domain which mediates 
DNA binding through two zinc-finger motifs; whereas the LBD is a less conserved 
domain and mediates ligand binding, dimerization, and ligand-dependent 
transactivation.  Such ligand-dependent transactivation is called activation function-2 
(AF-2), whereas the A/B region harbors a ligand-independent transactivation domain 
named AF-1 (Bourguet et al., 2000). 
Ligands of nuclear receptors are usually molecules of small volume, low 
weight, and are relatively hydrophobic (Bogan et al., 1998).  BAs are small 
amphipathic steroidal compounds, thus they have the preferred characteristics as 
nuclear receptor ligands.  So far, several nuclear receptors have been identified as 
BA sensors, including farnesoid X receptor (FXR), pregnane X receptor (PXR), 
vitamin D receptor (VDR), and constitutive androstane receptor (CAR).  These 
nuclear receptors mediate negative-feedback or feed-forward regulation of bile-acid 
biosynthesis, transport, and detoxification.  
BA sensors: FXR, PXR, VDR and CAR 
FXR as the BA sensor 
The identification of FXR as a BA sensor in 1999 (Makishima et al., 1999; 
Parks et al., 1999; Wang et al., 1999) shed light on the mechanism for negative-
feedback regulation of BA biosynthesis.  Various BAs can bind to and activate FXR, 
with the ranking of binding affinity: CDCA>DCA>CA>>LCA (Lew et al., 2004).  Like 
other class-II nuclear receptors, FXR is a heterodimer partner with retinoid X 
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receptor (RXR) (Mangelsdorf and Evans, 1995; Seol et al., 1995).  Various models 
have been proposed for the negative-feedback regulation of Cyp7a1, the first and 
rate limiting-enzyme in the classic BA biosynthesis pathway.   
Hepatic FXR-SHP-LRH-1 signaling pathway 
In this signaling pathway, upon binding of BAs, FXR heterodimerizes with 
RXR, which recognize and bind to an inverted repeat motif (IR-1) in the promoter of 
SHP (Small Heterodimer Partner), and up-regulates SHP gene expression.  SHP is 
an atypical nuclear receptor without a DNA-binding domain.  It interacts with various 
nuclear receptors, e.g LXR, PXR, LRH-1, HNF-4, etc through its N-terminal 
dimerization domain, and inactivates transactivation, mediated by the corresponding 
nuclear receptors (Lee et al., 2000; Brendel et al., 2002; Ourlin et al., 2003).  In the 
FXR-SHP-LRH-1 pathway, increased SHP protein binds to and inhibits LRH-1, 
which is necessary for activation of Cyp7a1 by LXR, resulting in decreased 
expression of Cyp7a1 (Goodwin et al., 2000).   
FXR-mediated SHP-independent pathways involved in feedback 
regulation of Cyp7a1 
Even though SHP is important in Cyp7a1 gene regulation (Boulias et al., 
2005), SHP-knockout mice show only a slight impairment in the negative-feedback 
regulation of Cyp7a1 (Kerr et al., 2002).  This suggests that other SHP-independent 
pathways may be present.  Holt and colleagues found a FGF19/FGF15-dependent 
pathway that involves Cyp7a1 gene expression (Holt et al., 2003).  In this pathway, 
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BA activated FXR in the enterocytes, causing increased expression of Fgf15.  The 
Fgf15 protein enters the portal blood and travels to the liver where it activates its 
receptor FGFR-4 on the hepatocytes, causing decreased expression of Cyp7a1.  
(Holt et al., 2003; Inagaki et al., 2005).  Further study using the strong FXR agonist 
GW4064 and tissue specific FXR null mice showed that the intestinal FXR is more 
important than the hepatic FXR in suppression of Cyp7a1 expression (Kim et al., 
2007; Chiang, 2009). 
βKlotho is also involved in the regulation of BA biosynthesis.  Ito and 
colleagues (Ito et al., 2005) showed that mice lacking βKlotho have increased 
Cyp7a1 expression and BA biosynthesis, and are resistant to the formation of 
gallstones.  βKlotho is structurally similar to Klothos protein, which is located on cell 
membranes. Both proteins belong to the type-1 membrane proteins and have 2 
family 1 glycosidase-like domains, but they lack enzyme activity domains (McCarter 
and Withers, 1994; Davies and Henrissat, 1995).  The tissue distribution of βKlotho 
is mainly in liver, adipose tissues, and pancreas (Ito et al., 2000).   βKlotho-KO and 
FGFR4-KO mice have similar phenotypes, including increased BA biosynthesis and 
small gallbladders, suggesting that these proteins may act through a common 
pathway (Moschetta and Kliewer, 2005).  Later, it was shown that βKlotho and 
FGFR4 are co-receptors mediating intracellular gene regulation by Fgf15.  Knock 
out of either FGFR4 or β-Klotho will abort the effects of Fgf15 on suppression of 
Cyp7a1 (Lin et al., 2007; Wu et al., 2007).   
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PXR as a BA sensor  
PXR can be  activated by a broad range of xenobiotics with dramatically 
different structures (Bertilsson et al., 1998; Blumberg et al., 1998; Kliewer et al., 
1998; Lehmann et al., 1998; Savas et al., 2000; Staudinger et al., 2001b).  Such 
ligand characteristics of PXR fit its structural features very well.  PXR has a highly 
conserved DNA-binding domain (DBD) with more than 90% identity among all its 
orthologs, and low conserved ligand-binding domain (LBD) with only about 70% 
identity among all of its orthologs (Bertilsson et al., 1998; Blumberg et al., 1998).  
Even though PXR is called the xenobiotic receptor, it can be activated by a 
variety of endogenous ligands, including BAs (Kliewer and Willson, 2002; Kliewer, 
2003; Wagner et al., 2005).  Upon activation by BAs, especially LCA, PXR regulates 
the expression of genes involved in BA metabolism and transport, for example, 
decreasing Cyp7a1 expression, as well as increasing the expression of Cyp3a 
enzymes and the efflux transporter Bsep (Makishima et al., 1999; Staudinger et al., 
2001a; Watkins et al., 2001; Xie et al., 2001; Eloranta and Kullak-Ublick, 2005; 
Wagner et al., 2005).  The overall effect of PXR activation is to decrease the 
concentration of BAs in hepatocytes and provide protective effects to the liver 
(Staudinger et al., 2001b; Kliewer and Willson, 2002).  
It has been known for over 30 years that PCN can reduce the expression of 
Cyp7a1 (Mason and Boyd, 1978).  PCN is an activator of mouse and rat PXR.  In 
PXR-null mice, inhibition of Cyp7a1 by PCN treatment is disrupted (Staudinger et al., 
2001a).  This finding provided direct evidence that PXR mediates negative 
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regulation of BA biosynthesis.   The finding that LCA is an endogenous activator for 
PXR (Staudinger et al., 2001b) suggested that PXR may play an important role in 
BA homeostasis.  In cholestatic patients, the concentration of LCA in liver reaches 5-
10 µM (Setchell et al., 1997).  The IC50 of LCA and its 3-keto metabolite to human 
PXR is ~10µM (Staudinger et al., 2001b).  These findings suggest that activation of 
PXR in cholestasis may provide an auto-protective mechanism for the liver.  PXR 
activation by LCA inhibits the gene expression of Cyp7a1 resulting in less BA 
synthesis.  Activation of PXR also increases gene expression of Cyp3a such that 
more water soluble BAs will be excreted into urine (Staudinger et al., 2001a). 
VDR as a BA sensor 
In addition to FXR and PXR, VDR was found to be another BA sensor, 
especially for LCA.  Like other nuclear receptor family members, VDR also has the 
standard module structure of nuclear receptors and it also heterodimerizes with RXR 
to fulfill its function upon binding by its activator, e.g. vitamin D. VDR mediates 
important homeostasis with regard to calcium.  In addition, VDR also affects 
differentiation and function of cells in the immune system (Liblau et al., 1995), and 
functions as a receptor for LCA (Makishima et al., 2002).  They reported that at 
concentrations much lower than that needed for activation of either PXR 
(EC50=100µM) or FXR (EC50=7µM), LCA can activate VDR in the intestine 
(Makishima et al., 2002).  Activated VDR can up-regulate its target gene Cyp3A 
(Schmiedlin-Ren et al., 1997; Thummel et al., 2001), which metabolizes LCA and 
many drugs.  Thus the VDR in the intestine provides another protective mechanism 
20 
for the body to diminish the toxic effects of LCA, namely, activated VDR may 
increase the degradation of LCA in the intestine before it reaches the liver through 
the portal system.   
CAR as a BA sensor  
CAR is a nuclear receptor that resides close to the cell membrane by forming 
part of a protein complex with the membrane-associated subunit of protein 
phosphatase 1 (PPP1R16A, abbreviated as R16A) protein (Sueyoshi et al., 2008).  
Upon stimulation by a CAR inducer, such as phenobarbital, two R16A subunits 
dimerize and inhibit the activity of protein phosphatase 1β, triggering CAR 
translocation into the nucleus. In addition, dephosphorylation of threonine 38 of CAR 
is also necessary for its nuclear translocation and activation (Mutoh et al., 2009). 
Inside the nucleus, CAR functions to modulate the transactivation of its target genes 
(Sueyoshi et al., 2008).  CAR is considered mainly as a xenobiotic nuclear receptor, 
however CAR activators also include endobiotics, such as BAs, especially toxic LCA 
(Guo et al., 2003; Qatanani and Moore, 2005).  BAs at high concentrations can 
induce a CAR target gene sulfotransferase Sult2a1 (Ding et al., 2006).  Sult2a1 
catalyzes the sulfonation of LCA under normal conditions and other BAs under 
cholestatic conditions (Chen et al., 1978; Macrides et al., 1994).  Increased BA 
sulfates contribute to enhanced urinary elimination of BAs, and thus decrease the 
toxicity of BAs.  A recent study demonstrated that loss of both PXR and CAR in mice 
increases their sensitivity to BA toxicity (Uppal et al., 2005), indicating important 
roles of both PXR and CAR in regulating BA homeostasis.  
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Other factors that mediate BA regulation of BA homeostasis 
BAs can activate multiple isoforms of protein kinase C (PKC) (Stravitz et al., 
1995; Stravitz et al., 1996).  Activated PKC leads to repression of Cyp7a1 (Stravitz 
et al., 1995).  BAs can activate macrophages in liver, which then produce TNFα.  
The latter molecule can activate JNK (c-jun N-terminal kinase) (Miyake et al., 2000).  
It has been suggested that the JNK-mediated pathway may crosstalk with the FXR-
SHP mediated pathway through activation of SHP-1 (Gupta et al., 2001).  
The BARE (bile acid response element) in the Cyp7a1 promoter region has a 
binding motif for HNF4α (Crestani et al., 1998).  Upon binding to the promoter, 
HNF4α recruits coactivators to the Cyp7a1 promoter region, leading to the induction 
of Cyp7a1. The transcriptional activity of HNF-4α on Cyp7a1 is repressed by the c-
jun N-terminal kinase (JNK) signaling pathway (De Fabiani et al., 2001).  The 
underlying mechanism for such repression is thought to be due to phosphorylation of 
HNF4α and subsequent dissociation of PGC-1α (PPAR gama coactivator-1α) and 
CREB-binding protein (CBP) from HNF4α (De Fabiani et al., 2003).   
BA regulation of transport 
Liver is a detoxification organ for many chemicals, and has various types of 
transporters in hepatocyte membranes.  Numerous chemicals enter into and come 
out of hepatocytes.  The transport of many chemicals is mediated by specific 
transporters located in basolateral or canalicular membranes.  The transporters 
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involved in BA transport include: Ntcp, Oatps, Bsep, and Mrps  (Meier and Stieger, 
2002).  
Hepatic uptake of BAs at the basolateral surface of hepatocytes: 
The hepatic basolateral transporters, Na+/taurocholate cotransporting 
polypeptide (Ntcp), and organic anion transporting polypeptides (Oatps), are the 
main uptake transporters for BAs to enter hepatocytes.  Ntcp is the main sodium-
dependent transporter that transports BAs together with 2 Na+ across the 
hepatocyte membrane.  The sodium concentration gradient produced by Na+/K+ 
ATPase is the driving force for Ntcp to transport BAs across the hepatocyte 
membrane (Hagenbuch and Meier, 1994; Jacquemin et al., 1994; Kouzuki et al., 
2000; St-Pierre et al., 2001). 
Several members of the Oatp family Na+-independently transport BAs and 
other organic anions into hepatocytes. Rodent Oatp1a1 (previously called Oatp1), 
Oatp1a4 (previously called Oatp2) and Oatp1b2 (previously called Oatp4) are Oatps 
that are involved in bile-acid uptake by hepatocytes.  These Oatps are located in the 
sinusoid membrane of hepatocytes (Jacquemin et al., 1994; Kouzuki et al., 2000; 
Cattori et al., 2001)  
Hepatic excretion of BAs at the canalicular/apical surface of 
hepatocytes:   
BAs are actively pumped out of hepatocytes into the canaliculi through 
canalicular ATP-binding cassette (ABC) transporters.  Amino acid conjugated BAs 
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are mainly exported by the bile salt export pump (Bsep).  The sulfated and 
glucuronidated forms of BAs are transported mainly by Mrp2 (Meier and Stieger, 
2002).  Mrp3 also mediates the excretion of BAs, but it mediates the transport of 
BAs from hepatocytes to sinusoids (Liblau et al., 1995; Hirohashi et al., 2000).  
Under cholestatic conditions, most transporters involved in BA transport are down-
regulated, with the exception of Mrp3 which is up-regulated.  The up-regulation of 
Mrp3 is thought to be a compensatory mechanism that the body uses to eliminate 
extra BAs from hepatocyte to blood, for further excretion into urine (Soroka et al., 
2001).  
1.2.3  BA Regulation of Lipid Homeostasis 
It is well established that BAs regulate cholesterol homeostasis by facilitating 
its elimination into bile.  In addition, BAs also affect triglyceride homeostasis. 
Clinically, treatment with cholestyramine resin for hypercholesterolemia causes 
increased VLDL (Grundy et al., 1971; Nestel and Grundy, 1976).  The inhibitory 
effects of BAs on the biosynthesis of hepatic fatty acids and the production of VLDL 
are mediated by the FXR-SHP signaling pathway (Watanabe et al., 2004).  SHP 
decreases the expression of sterol regulatory element-binding proteins (SREBPs), 
the transcription factors controlling cholesterol homeostasis.   
1.2.4  BA Regulation of Energy Homeostasis 
The effects of BAs on energy homeostasis was noticed by their inhibition of 
diet-induced obesity.  The finding of a novel G protein-coupled cell-surface BA 
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receptor, TGR5, in brown fat tissue and skeleton muscle provided the mechanistic 
basis for BA regulating energy homeostasis (Maruyama et al., 2002; Kawamata et 
al., 2003; Watanabe et al., 2006).  Briefly, CA can bind and activate TGR5 that 
triggers an intracellular signaling pathway, including increased production of cAMP 
(Houten et al., 2006).  This signaling pathway increases the activity of type 2 
iodothyronine deiodinase (D2), which increases the  conversion of inactive thyroid 
hormone T4 to the biologically active T3, resulting in an increased metabolic rate 
(Watanabe et al., 2006).  
1.2.5  BA Regulation of Glucose Homeostasis 
Classically, BAs are identified as endogenous detergents facilitating lipid 
absorption and cholesterol homeostasis.  Recent progress in BA research indicates 
that BAs may be very important in regulating glucose homeostasis.   The possible 
regulatory effects of BAs on glucose homoestasis were noticed more than ten years 
ago.  The hyperglucosemic condition in patients with both hyperlipidimia and type 2 
diabetes was improved, after  treatment with the BA sequestrant cholestyramine 
(Garg and Grundy, 1994).  In 2003, it was found that BAs regulate gluconeogenesis 
in a FXR-dependent way (De Fabiani et al., 2003).  In 2004, BAs were also found to 
be able to regulate glucose homeostasis in a SHP-dependent way (Yamagata et al., 
2004).  
Up to now, several mechanistic hypothesis have been proposed for BA 
regulation of glucose homeostasis:  1). BAs stimulate glycogen phosphorylase  (GP) 
via mobilization of intracellular calcium, which results in an increase in the 
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breakdown of glucogen to glucose-1-phosphate  (Bouscarel et al., 1993; Matsuzaki 
et al., 1997; Fang et al., 2007).  2). BAs induce the expression of 
phosphoenopyruvate carboxykinase (PEPCK) via activation of FXR. Activated FXR 
also increases insulin sensitivity resulting in decreased serum glucose levels (Ma et 
al., 2006; Zhang et al., 2006).   
 It was also reported that various BAs have different effects on 
gluconeogenesis.  UDCA treatment seemed to be able to increase glycogen 
breakdown, in contrast, CA and DCA treatments seemed to be able to cause 
synthesis of glycogen (Zhang et al., 2006).  More research is needed to address the 
different effects of BAs on glucose metabolism.  
1.3 Hepatotoxicity of BAs  
1.3.1  Cholestasis 
Bile formation is a critical function of the liver.  Normal bile formation depends 
on four factors: 1) Integral transmembrane transport systems: actively transporting 
BAs and other solutes to generate the osmotic gradients for bile flow, 2) intact 
cytoskeleton system: moving vesicles across the hepatocytes and maintaining 
normal bile canalicular contractions,  3) cell-cell connections: sealing off the bile 
canaliculi and maintaining cell polarity, and 4) normal signal transduction: regulating 
and coordinating the various processes involved in bile formation (Burwen et al., 
1992).  Any disruptions interfering the above four aspects of normal bile secretion 
can cause cholestasis  (Popper and Schaffner, 1963).  During cholestasis, retention 
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of hydrophobic BAs within the liver causes major pathophysiologic changes in the 
liver (Greim et al., 1972; Fischer et al., 1996).   
Clinically, cholestatic liver diseases include a wide variety of hepatobiliary 
diseases of diverse etiologies that are characterized by impaired hepatocellular 
secretion of bile, resulting in the accumulation of BAs, bilirubin, and cholesterol. 
Pharmacological therapy for cholestasis is limited. Thus, to provide new therapeutic 
management of cholestatic liver diseases, it is critical to fully understand the 
mechanisms of BA toxicity.  Several cholestatic liver injury models have been used 
to study  the mechanisms of BA toxicity, including common bile duct ligation, drug 
induced cholestasis (e.g. α-naphthyl-isothiocyanate, ANIT, induced cholestasis), and  
BA over-loading induced cholestasis  (Plaa and Priestly, 1976).  
Concept, symptoms/signs and morphology of cholestasis 
The hepatotoxicity of BAs was initially noticed under pathological conditions, 
namely cholestasis.  Cholestasis is defined as the blockage or impairment of bile 
secretion and bile flow with retention of BAs and other bile components inside the 
liver and body.  Cholestasis may arise as a functional secretory disturbance of 
hepatocytes and/or any obstruction occurring from the level of the liver 
parenchymal cells to the Papilla of Vater in the duodenum (Desmet, 1995).  Based 
on the location of the primary injury in the bile secretory path, cholestasis can be 
classified as intrahepatic cholestasis or extrahepatic cholestasis. In intrahepatic 
cholestasis, the injured bile secretion is primarily present inside the liver, including 
diseases at the hepatocyte level and diseases at the intrahepatic bile duct level.  In 
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extrahepatic cholestasis, the bile excretory blockage is present outside the liver 
along the extrahepatic bile ducts, thus it is also called obstructive cholestasis 
(Desmet, 1995). 
 A common consequence of cholestasis is hepatic and systemic 
accumulation of toxic biliary compounds, such as bilirubin, cholesterol, and BAs, 
especially the toxic lithocholic acid (LCA) whose level is 3-5 times higher in 
cholestasic than normal liver (Attili et al., 1986; Schmucker et al., 1990; Heuman et 
al., 1991; Trauner et al., 1998).  Increased BA concentrations in liver contribute to 
the pathophysiological and histological changes in liver, including increased serum 
levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
alkaline phosphatase (AP), and total bilirubin, hepatic necrosis, and lymphocytic 
infiltration mediated inflammation.  In the final stage of cholestasis, liver fibrosis 
usually occurs, which often requires a liver transplant to save  the patient’s life (Li 
and Crawford, 2004).   
In addition, cellular ultrastructural changes are observed in cholestatic liver 
diseases.  Under the electron microscope, the canaliculi usually dilate and lose their 
microvilli (Schaffner and Popper, 1959).  Cells around the abnormal canaliculi have 
characteristic ultrastructure changes:  Denser cytoplasm than normal, increased 
smooth endoplasmic reticulum, and dilated profile of the Golgi zone.  In the 
abnormal canaliculi, bile plugs are often seen.  The bile plugs are mixtures of 
polysaccharide and two types of deposits: a deposit of pigment in a finely fibrillar 
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shape, and a deposit of liquid crystals of lecithin/cholesterol/BA mixture (Popper 
and Schaffner, 1963; Biava, 1964a; Biava, 1964b; Popper, 1968).    
Hepatotoxicity of BAs during Cholestasis and the Mechanisms for their 
Hepatotoxicity 
BA induced liver cell death: apoptosis and necrosis    
Apoptosis as well as necrosis are common features in cholestatic liver 
diseases, or in experimental cholestatic disorder models, such as bile duct ligation, 
ANIT-induced cholestasis, or LCA feeding induced cholestasis (Desmet et al., 1968; 
Rodriguez-Garay, 2003; Fickert et al., 2006; Hatano, 2007).  Even though cell death 
during cholestasis might be caused by multiple factors, it is evident that BAs, 
especially relatively hydrophobic BAs, are responsible for both apoptotic and 
necrotic cell death (Gujral et al., 2004b; Li and Crawford, 2004).   
All BA molecules are comprised of two parts, the hydrophobic steroid nucleus 
and the hydrophilic side chain. The addition of hydroxyl groups on the steroid 
nucleus increases the water solubility of BAs.  The amphipathic characteristics of 
BAs give them detergent like activities (Hofmann and Small, 1967).  Such detergent-
like properties of BAs make them good solvents for cholesterol under physiological 
conditions.  However, the surfactant effects of BAs also make them toxic to cell 
membranes, causing cell swelling, and cell death.  The more hydrophobic a BA is, 
the more toxic to the membrane is the BA (Scholmerich et al., 1984; Attili et al., 
1986).  After incubation of different BAs with primary rat hepatocytes, CA and TCA 
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did not cause cell damage, even at concentration of 1500 µM, whereas, CDCA and 
its taurine conjugates, and DCA cause cell lysis at concentrations above 500 µM.  
TDCA is more toxic than its unconjugated counterpart DCA in damaging the cellular 
membrane.  Whereas, the most hydrophobic BA, TLCA, at concentrations as low as 
30 µM, caused cell lysis.  Accordingly, BAs during cholestasis might cause necrosis 
due to their detergent-like effects. 
 Apoptosis is programmed cell death.  Apoptosis is characterized by 
distinctive morphological changes: shrinkage of the cells, condensation of nuclear 
chromatin against the nuclear membrane, DNA fragmentation, and formation of 
acidophilic bodies or apoptotic bodies in the liver (Searle et al., 1982).  Two main 
signaling pathways are involved in BA-induced apoptosis: one is the death-receptor-
mediated apoptosis (extrinsic pathway), the other is the mitochondria-dysfunction-
mediated apoptosis (intrinsic pathway) (Jaeschke et al., 2002; Hatano, 2007).   
Mechanisms for Cytotoxicity of BAs: Death Receptor Mediated 
Cytotoxicity  
BAs cause hepatocyte apoptosis partially via activation of the death receptor, 
such as the TNF-α receptor, during cholestasis (Hatano, 2007).  But in TNF-receptor 
knock-out mice, apoptosis was still present after bile-duct ligation, suggesting that 
other signaling pathways may be involved in BA-induced apoptosis.  It was also 
found that the toxic effects of CDCA was partially due to its direct activation of the 
death receptor Fas/CD95, which leads to hepatocyte apoptosis (Faubion et al., 
1999).  Further research found that BAs can increase transport of FAS from cytosol 
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to the plasma membrane of hepatocytes to enhance the FAS-mediated apoptotic 
process (Faubion et al., 1999; Sodeman et al., 2000; Jaeschke et al., 2002).  An in 
vitro study showed that glycine-conjugated chenodeoxycholic acid (GCDCA) 
induces apoptosis via activation of FAS (Patel et al., 1994).  Fas activation by BAs is 
initiated by a NADPH oxidase derived oxidative stress signal (Reinehr et al., 2005) 
that activates c-Jun-N-terminal kinases (JNK) (Leppa and Bohmann, 1999) and the 
Src Kinase family member Yes.  Activated Yes rapidly activates the epidermal-
growth-factor receptor (EGFR) (Reinehr et al., 2003) that catalyzes FAS tyrosine 
phosphorylation in a JNK-dependent way.  The phosphorylation of FAS leads to 
FAS-membrane trafficking, formation of the death-inducing signalling complex (DISC) 
and induction of apoptosis (Reinehr and Haussinger, 2007).  
Except for the classic death receptor, via which BAs induce apoptosis, BAs 
can cause recruitment of caspase-8 into the death-inducing signaling complex 
(DISC), and hepatocyte apoptosis via activation of cellular surface receptor TGR5 
and JNK signaling (Yang et al., 2007).   
Mechanisms for Cytotoxicity of BAs: Mitochondria Medicated BA 
Cytotoxicity 
The other mechanism via which hydrophobic BAs cause liver injury is  a 
mitochondria-mediated pathway.  Hydrophobic BAs can cause increased production 
of reactive oxygen species (ROS) via mitochondria, or via activation of NADPH 
oxidase (Sokol et al., 1995; Rolo et al., 2003a; Becker et al., 2007).  ROS cause 
opening of mitochondria permeability transition pores (MPTP) in the inner 
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membrane.  Non-permeable solutes that normally are unable to enter the 
mitochondria can freely enter the mitochondria via the MPTP, causing 
depolarizaqtion of the mitochondria membrane and failure to synthesize ATP.  
Dysfunctional mitochondria then release cytochrome c, which causes caspase 
activation, and further triggers mitochondria-mediated cell death (Kantrow et al., 
2000; Halestrap and Brennerb, 2003).  The generation of ROS is critical for MPT, as 
antioxidants and cyclosporine A (CsA) protect cultured hepatocytes from BA-
induced cell death (Gores et al., 1998; Yerushalmi et al., 2001; Rolo et al., 2003a; 
Rolo et al., 2003b; Rolo et al., 2004). 
Inflammatory liver injury during cholestasis 
Neutrophil infiltration is a common feature of cholestatic liver diseases (Louis 
et al., 1998; Thompson et al., 1998; Gujral et al., 2003; Li and Crawford, 2004; 
Fickert et al., 2006).  It has been concluded that neutrophil mediated inflammation 
contributes to liver injury during cholestasis (Jaeschke et al., 2002; Gujral et al., 
2004a; Kodali et al., 2006).  One chemical known for its inflammation-mediated 
hepatotoxicity is α-naphthylisothiocyanate (ANIT).  ANIT causes hepatotoxicity in a 
neutrophil-dependent manner.  Even though ANIT can cause direct cell death,  
neutrophil infiltration is thought to worsen the liver injury (Dahm et al., 1991).   
During cholestasis, the increased concentrations of hydrophobic BAs might initiate 
the liver cell injury. The injured liver cells then release various cytokines and 
chemokines that contribute to the neutrophil infiltration into the liver and subsequent 
exacerbation of liver injury.  Several critical steps are involved in neutrophil 
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infiltration into the liver and its killing of hepatocytes: Priming or systemic activation 
of neutrophils and accumulation of neutrophils in the liver vasculature, extravasation, 
and adherence to hepatocytes are thought to execute the cytotoxic effects 
(Jaeschke et al., 2002; Fickert et al., 2006; Ramaiah and Jaeschke, 2007). 
Proinflammatory mediators, such as cytokines and chemokines are critical in 
neutrophil-mediated liver injury.   To extravate the vasculature system into the 
parenchyma of the liver, the mechanically trapped neutrophils in the vasculature of 
the liver may interact with intercellular adhesion molecule (ICAM-1) or vascular 
adhesion molecule (VCAM-1) of the liver cells via integrin β1 molecules. The 
extravasation process of the neutrophils is also a process for full activation of the 
neutrophils.  The superoxide and proteases produced by the activated neutrophils 
via NADPH oxidase and degranulation causes further release of cytokines, which 
promotes further inflammation and hepatocyte oncotic necrosis (Fickert et al., 2006).  
Chronic liver damage usually leads to liver fibrosis.  Activation of hepatic 
stellate cells (HSCs) is thought to be a critical step during liver fibrogenesis 
(Svegliati-Baroni et al., 2008).  During chronic liver injury, including cholestasis,  
HSCs are activated by proinflammatory cytokines or growth factors, such as tumor 
necrosis factor α (TNFα) and transforming growth factor β1 (TGFb1) (Leyland et al., 
1996; Saile and Ramadori, 2007).  The activated HSCs are proliferative and are 
transformed from vitamin A storing cells into myofibroblasts.  The activated HSC 
also produce more extracellular matrix (ECM), including type 1 collagen 
(coallagen1a) (Saile and Ramadori, 2007; Svegliati-Baroni et al., 2008).   
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1.3.2  Hepatotoxicity of Individual BAs  
The toxicity of BAs is related to their detergent-like features.  The more 
hydrophobic, the stronger the detergent-like effects and the membrane damaging 
effects of BAs (Hofmann and Small, 1967; Vyvoda et al., 1977; Desmet, 1995). 
According to their hydrophobicity, the ranking of cytotoxicity of individual BAs is as 
follows:  CA<CDCA<DCA<LCA (Vyvoda et al., 1977; Attili et al., 1986).  
Hepatotoxicity of CA 
The toxic potency of BAs has been inversely correlated with their relative 
hydrophilicity.  Among all major human BAs, CA has three hydroxyl groups and 
thus relatively hydrophilic and less toxic compared to other mono- or di-hydroxy 
BAs, such as CDCA, DCA or LCA.  However, when CA concentration reaches a 
certain level, CA can be toxic.  After feeding CA to mice at concentrations of either 
0.5 or 1.0% in the diet for two weeks, serum ALT and AST in mice increased 
slightly (Delzenne et al., 1992).  Another in vivo study showed that after feeding 
1.0% CA for 7 days, mice lost their canalicular villi in addition to canalicular 
dilatation (Fickert et al., 2001). In the latter study, the mechanism of the toxic effects 
of CA was attributed to its effects on the cytoskeleton.  
Feeding mice 0.5% and 1.0% CA for 7 days caused an increase in serum 
enzymes, including alanine aminotransferase (ALT) and alkaline phosphatase (AP), 
suggesting that at the dose of 0.5% in the diets CA caused hepatocyte and bile duct 
damage.  Feeding CA also caused increased mRNA and protein expression of 
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cytokeratin 8 (CK-8). The increased expression of CK-8 is usually found in livers of 
bile duct ligated animals, and is considered a compensatory reaction to cholestatic 
liver injury (Fickert et al., 2002).  In another study, feeding mice 1% CA caused an 
increase in serum ALT and lipid deposition in livers (Wang et al., 2003b).  Livers of 
adult female hamsters fed 0.5% CA resulted in severe ductular/ductal proliferation 
and inflammatory infiltration (Siviero et al., 2008).   
The hepatotoxicity of CA is also observed in in vitro studies.  For example, at 
concentration of 1mM, CA progressively causes cell lysis (Delzenne, 1992).  
Another in vitro study showed that among CA and its conjugates, the glycine-
conjugated CA (GCA) is the most toxic CA (Martinez-Diez et al., 2000).  At 1mM, 
GCA caused decreased cell viability, whereas, both unconjugated CA and taurine-
conjugated CA (TCA) did not affect cell viability (Martinez-Diez et al., 2000).       
Both in vivo and in vitro studies demonstrated that compared to other 
relatively hydrophobic BAs (CDCA, DCA, and LCA), CA is less toxic (Delzenne, 
1992, Martinez-Diez et al. 2000). At a concentration of 1mM, CA caused direct cell 
lysis. 
Hepatotoxicity of CDCA 
CDCA, a primary BA in humans, has been used for the treatment of 
cholesterol gallstones for more than forty years. Treating rhesus monkeys or 
gallstone patients with CDCA caused increased serum ALT and histological 
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changes in the livers (Dyrszka et al., 1975; James et al., 1975).   During cholestasis, 
the concentration of CDCA increased about 20 fold (Greim et al., 1973a).  
CDCA is implicated most in cholestatic liver injury. CDCA is directly cytotoxic 
to hepatocytes (Miyazaki et al., 1984). In vitro studies showed that glycine-
conjugated CDCA (G-CDCA) caused ATP depletion, and mitochondria disfunction 
(Spivey et al., 1993; Rolo et al., 2001).  The toxic effects of CDCA have been 
suggested to be partially due to its direct activation of  death receptor Fas, which 
leads to  hepatocyte apoptosis (Faubion et al., 1999).  Among all CDCA species, G-
CDCA is the most toxic CDCA, followed by unconjugated CDCA, and the least toxic 
is the TCDCA (Spivey et al., 1993).  The concentration used for CDCA to produce 
cytotoxicity was 50µM (Rolo et al., 2004).  
Hepatotoxicity of DCA  
DCA is the secondary BA derived from CA. Similar to CDCA, DCA is a di-
hydroxy BA.  DCA can cause liver necrosis and apoptosis at high concentrations 
(Kwo et al., 1995).  In cell cultures, at 1000µM, all DCA species, including DCA, 
GDCA and TDCA, resulted in decreased cell viability (Martinez-Diez et al., 2000).  
DCA was also found to cause cell proliferation in both in vitro and in vivo studies 
(Cohen and Raicht, 1981).  
Hepatotoxicity of LCA  
LCA is the most hydrophobic BA among the four major human BAs,  thus 
LCA is thought to be the most toxic BA and produces lithogenic effects (Palmer and 
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Ruban, 1966).  However, in 1993, an in vivo study demonstrated that in rats, LCA 
was less toxic than the less hydrophobic BA DCA (Delzenne et al., 1992).  In whole 
animal studies, LCA at concentrations of 0.5 or 1.0% in the diets caused liver 
necrosis, apoptosis, and obstructive liver damage (Fickert et al., 2006).  In rats, 
TLCA infusion caused cholestasis, loss of canalicular microvilli, lamellar 
transformation of the canalicular membrane, and occasional crystalline precipitates 
within the canalicular lumen and in the pericanalicular region of hepatocytes (Miyai 
et al., 1977).  
1.4      Statement of Purposes  
1.4.1  General Background 
BAs are endogenous derivatives of cholesterol that facilitate the digestion and 
absorption of lipids and lipid soluble vitamins from the intestine.  During the last 
decade, more and more physiological importance of BAs have been revealed 
because of the discovery of the BA receptor FXR (Makishima et al., 1999; Parks et 
al., 1999; Wang et al., 1999).  Upon activation of FXR, BAs regulate the 
homeostasis of BA themselves (Ananthanarayanan et al., 2001; Chen et al., 2001; 
Denson et al., 2001), as well as lipids (Huang et al., 2003; Watanabe et al., 2004).  
One target gene of FXR is the small heterodimer protein (SHP), which is a repressor 
(Goodwin et al., 2000).  Via activation of FXR and FXR-SHP mediated signaling 
pathways, BAs coordinately regulate BA biosynthesis and transport, including 
inhibition of the key enzyme of BA biosynthesis Cyp7a1 (Goodwin et al., 2000) and 
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the uptake transporter Ntcp (Denson et al., 2001), and induction of BA efflux 
transporter Bsep (Ananthanarayanan et al., 2001; Plass et al., 2002).  
Despite their physiological importance, the detergent-like properties of BAs 
make them toxic to cellular membranes, and increased concentrations of free BAs 
can result in damage to tissues such as liver and bile duct (Delzenne et al., 1992; 
Wang et al., 2003c; Fickert et al., 2006).  In cholestatic disorders, or BA-feeding 
animal models, markedly increased BA concentrations in liver are thought to 
contribute to liver damage (Bremmelgaard and Alme, 1980; Fischer et al., 1996; 
Fickert et al., 2006).  Based on cholestatic disease models, conclusions have been 
made that increased concentrations of BAs in liver cause down-regulation of mRNA 
of genes involved in BA biosynthesis and BA uptake, as well as up-regulation of BA 
efflux transporter genes (Denson et al., 2001; Fickert et al., 2001; Zollner et al., 
2003b; Ando et al., 2005).  However, these internal compensatory changes could be 
the result of the toxic effects of BAs.  Thus, knowing the difference between the 
effects of non-hepatotoxic doses of BAs and hepatotoxic doses of BAs is critical to 
proper appreciation of the physiological/pharmacological functions of BAs and the 
hepatotoxic effects of BAs.  Therefore, the ultimate goal of the present dissertation is 
to identify which genes involved in BA biosynthesis and transport are regulated by 
BAs and possible roles of hepatic FXR and ileum FXR-Fgf15 in regulating these 
genes by feeding mice non-hepatotoxic doses of BAs.   
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1.4.2  Specific Research Hypothesis and Aims 
Hypothesis 1:  The doses of BAs (0.5 or 1.0% in the diet) used in most BA 
research in literature are hepatotoxic. 
Rationale: It is thought that DCA and LCA are the most toxic BAs among the 
five BAs, namely CA, CDCA, DCA, LCA and UDCA.  However, as the father of 
toxicology Paracelsus said: the dose makes a thing toxic.  Therefore, in the present 
dissertation, it was expected that even the most hydrophilic BA CA would be toxic 
when administered at an appropriate dose.  In addition, it was also expected that 
introducing one BA into the body would change the profile of other BAs in liver.  
However, at the present time, it is not known what dose of the major human BAs are 
hepatotoxic. Therefore, histopathological, biochemical and analytical methods were 
employed in the first study to characterize the hepatotoxicity of each of the five 
individual BAs and to determine the non-hepatotoxic doses and hepatotoxic doses 
of each BA.  A central hypothesis of the present dissertation is that the non-
hepatotoxic doses of BAs regulate genes differently from hepatotoxic doses of BAs 
because the hepatotoxic doses of BAs result in toxic effects which confound the 
physiological effects of BAs.  
Specific Aim 1a. Characterize the lethality and hepatotoxicity of each BA in 
mice and determine the non-hepatotoxic and hepatotoxic concentrations of each BA 
in their feed using both serum ALT activity and serum BA concentration as 
standards. 
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Specific Aim 1b. Determine total liver BA concentrations and analyze the BA 
composition in livers of mice fed various concentrations of BAs in their feed. 
Hypothesis 2. Non-hepatotoxic doses of BAs fully activate hepatic FXR as 
hepatotoxic doses of BAs do. 
Rationale: BAs are thought to regulate their own homeostasis mainly via 
their sensor FXR (Makishima et al., 1999; Parks et al., 1999; Wang et al., 1999).  
Via activating FXR, BAs up-regulate the efflux transporters Bsep and Mrp2.  Via 
activating FXR-SHP signaling, BAs down-regulate BA synthesis enzymes and 
uptake transporters in liver (Goodwin et al., 2000).  In addition, the intestinal FXR-
Fgf15 signaling pathway is also thought to regulate the liver biosynthesis enzyme 
Cyp7a1 (Inagaki et al., 2005).  Fgf15 in the mouse intestine has been shown to be 
induced by CA-feeding, and is thought to travel via the portal vein to the liver where 
it will activate the cell surface fibroblast growth factor receptor (FGFR) 4, triggering 
the intracellular signaling pathway that represses the expression of  hepatic Cyp7a1.  
Data generated by feeding mice hepatotoxic concentrations of BAs might not 
reflect the true physiological functions of BAs.  Thus, the goal of this study was to 
determine which FXR mediated signaling pathway plays a main role in regulating 
genes involved in BA homeostasis in mice using all five BAs at non-hepatotoxic 
doses as FXR activators. 
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Specific Aim 2a.  Determine whether FXR, FXR-SHP signaling in the liver, 
and FXR-Fgf15 signaling in the ileum are activated by feeding mice non-hepatotoxic 
doses of five individual BAs 
Specific Aim 2b.  Determine which genes involved in BA biosynthesis and 
BA transport are regulated by BAs, as well as possible roles of FXR-SHP signaling 
in liver and FXR-Fgf15 signaling in ileum in regulating BA regulated genes.  
Hypothesis 3.  Reduced total BA concentrations in the livers of mice fed the 
BA sequestrant cholestyramine (resin) results in diminished activation of FXR in liver 
and decreased signaling of FXR-Fgf15 in ileum.  After resin-feeding, the mRNA 
expression of genes regulated by BAs will be opposite to that after BA-feeding. 
Rationale:  Cholestyramine, a non-absorbable ionic exchange resin, is a 
cholesterol lowering drug by binding BAs in the intestine and increasing their fecal 
excretion (Thompson, 1971).  In addition, resin has been used as a BA-pool-size 
lowering chemical for studying the functions of BAs.  The decreased enterohepatic 
circulation of BAs results in increased catabolism of cholesterol into BAs.  The 
ultimate mechanism for decreasing cholesterol is the increase in mRNA expression 
and enzyme activity of Cyp7a1, which is the rate limiting enzyme in BA biosynthesis, 
after resin treatment (Thompson, 1971; Nilsson et al., 2007).  Even though resin is a 
non-absorbable drug, it has been found to regulate glucose homeostasis and to 
improve atherosclerotic coronary heart disease (CHD), which is thought to have little 
to do with its lipid lowering effects.  The binding efficiency of various BAs to resin 
varies (Thompson, 1971).  At the pH of the intestine (about 6.0), the relatively 
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hydrophobic BAs (DCA and LCA) bind stronger to the resin than the hydrophilic BAs 
(CA and MCA) (Whiteside et al., 1966; Thompson, 1971; Story and Kritchevsky, 
1976).  Thus, feeding mice the resin is likely to not only decrease BA concentrations, 
but also alter the BA composition, as well as to change gene expression in liver and 
intestine.  Therefore, the purpose of this study was to determine the effects of resin 
on BA concentrations and composition in livers of mice, as well as gene expression 
of enzymes, transporters, and transcription factors in both liver and ileum known to 
be involved in biosynthesis or transport of BAs.  
Specific Aim 3a:  Determine the BA concentrations in livers of mice fed 2% 
cholestyramine resin for one week 
Specific Aim 3b:  Determine the effects of feeding mice the resin on FXR 
signaling in the livers and the FXR-Fgf15 signaling in the ilea. 
Specific Aim 3c:  Determine the effects of resin on mRNA expression of 
genes involved in BA-biosynthesis and BA-transport in livers and ilea of mice. 
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CHAPTER TWO 
MATERIALS AND METHODS 
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2.1 Chemicals: All BAs, including CA, CDCA, DCA, LCA, and UDCA, as well 
as cholestyramine resin, were purchased from Sigma Chemical Co. (St Louis, MO, 
USA).  
2.2 Preparation of BA or resin Supplemented Diets:  Pelleted mouse feed 
(Teklad Rodent Diet #8604, Harlan Teklad, Madison, WI) was ground into a fine 
powder.  CA, CDCA, and DCA were granular and thus were ground into a fine 
powder using a mortar and pestle.  Each BA at proper weight, or resin at proper 
weight, was subsequently thoroughly mixed with the finely ground feed using an 
electronic mixer to obtain the desired concentrations in the feed  
2.3 Animal Experiments:  Male C57BL6 mice (22 ± 2g) at 8 weeks of age 
were obtained from Charles River Laboratories, Inc. (Wilmington, MA).  The mice 
were housed and fed according to the American Animal Association of Laboratory 
Animal Care Guidelines.  Mice were housed with a 12:12 hr light:dark cycle, and 
provided mouse chow and water ad libitum.  Each mouse was housed in a single 
mouse cage and acclimated to the housing facility and ground control rodent diet for 
one week.  The diet was then exchanged to those supplemented with various 
percentages of BAs, including CA, CDCA, and DCA at final concentrations of 0.03, 
0.1, 0.3, or 1.0% (w/w), or LCA at 0.01, 0.03, 0.1, 0.3, or 1.0% (w/w), or UDCA at 0.1, 
0.3, 1.0, or 3.0% (w/w), or resin at 2% in the diet.  The BA or resin supplemented 
diets (40g) were added to a bowl in each mouse cage daily, and the remaining feed 
from the previous day was discarded. Cages were replaced daily to minimize 
contamination of feed with urine and feces.  After 7 days on these diets, serum 
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samples were collected and stored at 4°C for biochemical analysis, whereas, livers 
were removed, frozen in liquid nitrogen, and stored at -80°C.  Portions of livers were 
also fixed in 10% buffered formalin for histological studies.  
2.4  Biochemical analysis:  Serum ALT activity was quantified by an 
enzymatic-colorimetric assay using an ALT assay kit (Stanbio, Boerne, TX).  
2.5  Serum BA extraction:  For extraction of BAs from serum samples, 1 ml 
of ice-cold acetonitrile (ACN) was added to 100 µl of serum and mixed with 20 µI of 
internal standard (ISs: 2H4-G-CDCA and 2H4-CDCA at concentrations of 4 and 2 
µg/ml, respectively).  The mixtures were thoroughly vortexed and centrifuged at 
11,000 g for 10 min.  The supernatants were collected, evaporated under vacuum 
for 3 hrs at 50ºC, and reconstituted in 100 µl of methanol:water (1:1) (Alnouti et al., 
2008).  
2.6 Liver BA extraction: To extract BAs from liver samples, approximately 
120 mg of liver was homogenized in 5 volumes of H2O. Six hundred µl of liver 
homogenate was spiked with 10 µl of ISs, mixed, and equilibrated on ice for 10 min. 
Three ml of ice-cold alkaline acetonitrile (5% ammonia in acetonitrile) was added to 
the homogenate. The mixtures were then vortexed thoroughly and shaken 
continuously for 1 hr at room temperature. The mixtures were centrifuged at 12,000 
x g for 10 min. The supernatant was collected. The pellet was resuspended in 1 ml 
of methanol, sonicated for 5 min, and centrifuged at 12,000 x g for 10 min. The two 
supernatants so obtained were combined and evaporated under vacuum. The 
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deposit was then reconstituted in 100 µI of 50% methanol, vortexed, transferred into 
a 0.2 µm Costar Spin-X HPLC microcentrifuge filter (Corning Inc, Corning, NY), and 
centrifuged at 20,000 x g for 10 min. The supernatants were collected and analyzed 
using UPLC-MS/MS. 
2.7 BA separation and quantification by ultra performance liquid 
chromatography-tandum mass spectrometry (UPLC-MS/MS):   A Waters 
ACQUITY ultra performance LC system (Waters, Milford, MA) was used to separate 
and to quantify individual BA in serum and liver BAs extraction samples. All 
chromatographic separations were performed on an ACQUITY UPLC BEH C18 
column (1.7 µm, 100 X 2.1 mm I.D.). The detailed LC and mass spectrometric 
conditions were as described in a previous study (Alnouti et al., 2008). 
2.8 H&E staining of liver sections:  Livers were fixed using 10% buffered 
formalin overnight, dehydrated using various concentrations of alcohol, and 
embedded in paraffin. Paraffin embedded liver blocks were sectioned (5 µm thick). 
The sections were deparaffinized and rehydrated through a graded series of alcohol. 
Tissue sections (5 µm) were stained with hematoxylin and eosin (H&E) for general 
histopathology. Each liver section was visualized using an Olympus BX41 
microscope and photographed using an attached Olympus DP70 digital camera.   
2.9 Total RNA Extraction.  Total RNA was extracted from liver and ileum 
tissues using RNABee reagent (Tel-test Inc., Friendswood, TX) as suggested by the 
manufacturer’s protocol.  RNA was quantified by UV spectrophotometry at 260nm 
and diluted to 25 ng/µl in diethyl pyrocarbanate (DEPC)-treated deionized water.  
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2.10 QuantiGene Plex assay.  Messenger RNAs for mouse genes involved 
in BA homeostasis in liver and ileum were quantified using the QuantiGene Plex 2.0 
assay following the manufacturer’s protocol (Panomics/Affymetrix, Fremont, CA).  
Individual bead-based oligonucleotide probe sets were designed by 
Panomics/Affymetrix, Inc. using previously published NCBI gene accession numbers 
(www.panomics.com).  Briefly, isolated RNA (10 µl /well) was hybridized overnight at 
54˚C to specific oligonucleotide sequences corresponding to the genes of interest, 
which were bound to capture beads.  The following day the hybridized RNA, oligos, 
and capture beads were pipetted into corresponding wells of a filter plate.  The 
complex was then sequentially hybridized to first the pre-amplifier, followed by the 
amplifier, and lastly the biotinylated label probe (each for 1 hr at 50˚C).  Streptavidin-
PE was then allowed to bind for 30 min at room temperature and fluorescence was 
quantified by a Bio-plex suspension array system.  The housekeeping gene GAPDH 
was used to normalize the data. The data are expressed as a ratio of the target 
mRNA relative to GAPDH mRNA.  
2.11 Statistics. Differences between multiple groups were analyzed by one-
way ANOVA followed by Duncan’s post-hoc test. Statistical significance was 
considered at p<0.05.  
 
 
 
47 
CHAPTER 3 
IMBALANCED BILE ACID COMPOSITION IN LIVER CONTRIBUTES TO BILE 
ACID HEPATOTOXICITY IN MICE 
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3.1  Abstract 
BA feeding has been used to study BA signaling and toxicity in vivo.  
However, the concentration of BAs in the feed that is non-hepatotoxic is not well 
defined in mice.  Therefore, the purpose of this study was to determine the non-
hepatotoxic and hepatotoxic concentrations of five BAs in mouse feed, as well as 
the effect of feeding mice individual BAs on BA concentrations and BA composition 
in liver.  Mice were fed five individual BAs, cholic acid (CA), chenodeoxycholic acid 
(CDCA), deoxycholic acid (DCA), lithocholic acid (LCA), and ursodeoxycholic acid 
(UDCA) at 0.01, 0.03, 0.1, 0.3, 1.0, or 3.0% in their diets for 7 days.  The data 
showed: 1) LCA, DCA, and CDCA at 0.3% or lower in the diets were not lethal, but 
at the highest tested dose (1.0% in the diets) were lethal, whereas CA at 1% and 
UDCA at 1.0 and 3.0% were not lethal.  2) LCA produced hepatotoxicity at 0.03%, 
indicated by increases in serum ALT and serum BA concentration, as did DCA at 
0.1%, and CDCA and CA at 0.3% in the diet.  UDCA at 0.3% in the diet might be 
hepatotoxic because serum BA concentrations were increased, but the serum ALT 
did not increase.  3) Feeding BAs (CA, CDCA, DCA, or LCA) at hepatotoxic doses 
did not alter the total BA concentrations in liver; however it altered liver BA 
composition, including increases in the percentage of the fed BAs, and decreases in 
the percentage of muricholic acids.  In conclusion, it appears that an imbalance in 
BA composition in liver can contribute to BA hepatotoxicity.  In addition, to study the 
physiological or pharmacological functions of each BA, non-hepatotoxic 
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concentrations of BAs in the feed should be used, namely, CA, CDCA, and UDCA at 
0.1% or lower, DCA at 0.03% or lower, and LCA at 0.01% or lower in the diet.   
3.2  Introduction 
BAs are well known to facilitate the elimination of cholesterol into bile, as well 
as to act as emulsifiers for the absorption of lipids and lipid-soluble vitamins from the 
intestine.  Within the last decade, BAs have been found to be important signaling 
molecules playing critical physiological roles in regulating the homeostasis of BAs, 
cholesterol, glucose, and energy via activation of a number of nuclear receptors, 
including the farnesoid X receptor (FXR) (Makishima et al., 1999; Parks et al., 1999; 
Goodwin et al., 2000), pregnane X receptor (PXR) (Staudinger et al., 2001b; Xie et 
al., 2001), vitamin D receptor (VDR) (Makishima et al., 2002; Wolf, 2002), as well as 
the membrane receptor TGR5 (Kawamata et al., 2003; Katsuma et al., 2005; 
Watanabe et al., 2006).  
BAs are synthesized from cholesterol in the liver and secreted into the bile.  
In humans, the primary BAs are CA and CDCA, whereas in mice, CA and muricholic 
acids (MCAs, mainly β-MCA) are the primary BAs.  In bears, UDCA is the major BA. 
Primary BAs can be dehydroxylated by intestinal flora, producing secondary BAs: 
deoxycholic acid (DCA) from CA and lithocholic acid (LCA) from CDCA. MCAs, 
including α-MCA (3α,6β,7α-trihydroxy-5β-cholanoic acid), β-MCA (3α,6β,7β-
trihydroxy-5β-cholanoic acid), and ω-MCA (3α,6α,7β-trihydroxy-5β-cholanoic acid), 
can be 7-dehydroxylated to form murideoxycholate (MDCA) or its 6α-epimer 
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hyodeoxycholic acid (HDCA) by bacteria in the intestine (Lida et al., 1989; Miki et al., 
1993; Eyssen et al., 1999).  In humans, hyodeoxycholic acid (HDCA) is thought to 
be detoxification product of LCA in liver (Xie et al., 2001; Bodin et al., 2005).  
Toxic potency of various BAs is different, due to the number and optical 
orientation of the hydroxyl groups on the steroid nucleus. The primary BAs, CA and 
CDCA, are relatively more water soluble and less toxic than the secondary BAs, 
namely DCA and LCA (Mosbach, 1972; Salvioli et al., 1982).  Newly-synthesized 
BAs and deconjugated BAs from the enterohepatic circulation are conjugated with 
either glycine or taurine in liver.  Two enzymes are critical in the conjugation process: 
BAs-CoA ligase (BAL), which catalyzes the formation of BA-CoA, and BA-
CoA:amino acid N-acyltransferase (BAT), which amidates BA-CoA with the amino 
acid, glycine or taurine (Russell, 2003).  The BAT enzyme in humans and rats can 
conjugate BAs with either taurine or glycine (Falany et al., 1994), but the mouse 
BAT enzyme catalyzes conjugation of BAs predominantly with taurine (Falany et al., 
1997).  
Even though all BAs are derived from the precursor cholesterol, they have 
different physiological and pathological effects.  For example, CDCA is a more 
potent endogenous agonist of FXR compared to CA, DCA, or LCA (Makishima et al., 
1999; Parks et al., 1999);  CDCA and LCA can suppress LPS-induced TNF 
secretion in THP-TGR5 cells,  whereas UDCA can boost TNFα induction (Kawamata 
et al., 2003).  LCA is considered to be the most toxic BA and an activator of PXR 
(Staudinger et al., 2001b), whereas UDCA is thought to have hepato-protective 
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effects, and is thus used in the treatment of cholestatic liver diseases (Elias, 1999; 
Milkiewicz et al., 1999). 
To determine the physiological effects of BAs, BA supplemented diets have 
often been fed to laboratory animals (Oda et al., 1990; Murphy et al., 2005).  For 
example, mice fed 0.5 and 1.0% CA had decreased mRNA expression of the BA-
uptake transporter Ntcp (Fickert et al., 2001).  However, at such concentrations, CA 
caused liver injury, as indicated by an increase in serum ALT levels (Murphy et al., 
2005).  In contrast, some reports demonstrate that there is no hepatotoxicity for BAs 
at doses of 0.5 or 1% (Fickert et al., 2001).  These divergent reports indicate that the 
hepatotoxicity of individual BAs requires a systematic evaluation in a strictly-
designed experimental system.  Nevertheless, it is unclear whether the altered gene 
expression reported in many studies is the result of physiological concentrations of 
BAs, or is a consequence of BA toxicity.  Accordingly, determination of the non-
hepatotoxic and the hepatotoxic doses of individual BAs becomes very critical for 
proper interpretation of the gene regulation functions of individual BAs.  
In the present study, wild-type C57BL/6 mice were fed five individual BAs at 
various concentrations in their diets to investigate how individual BA-feeding 
influences the total liver BA concentration and liver BA composition.  In addition, 
both the serum ALT levels and the serum BA concentrations are used as indices of 
liver functions to determine the non-hepatotoxic concentrations and the hepatotoxic 
concentrations of individual BAs in the feed.  
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3.3  Results  
Effects of feeding BAs on survival, body weight, and liver weight.  The 
survival of mice fed various BAs at multiple concentrations in their diets for one 
week is shown in table 3-1.  All mice fed 0.01, 0.03, 0.1, and 0.3% of any BA (CA, 
CD CA, DCA, LCA or UDCA) in their diets survived.  However, 1.0% CDCA, DCA, 
and LCA were lethal, whereas all mice fed 1.0% CA survived.  Mice fed UDCA at all 
tested concentrations in the feed, including the highest dose of 3.0% in the diet, 
survived to the end of the study.  
 
Table 3-1.  Survival of mice fed bile acids at various 
concentrations in the feed for one week 
Conc 
(W/W%) CA CDCA DCA LCA UDCA 
0.01 - - - 5/5 - 
0.03 5/5 5/5 5/5 5/5 - 
0.1 5/5 5/5 5/5 5/5 5/5 
0.3 5/5 5/5 5/5 5/5 5/5 
1.0 5/5 0 0 0 5/5 
3.0 - - - - 5/5 
 
The BAs did not have a marked effect on body weight of mice (Fig 3-1), 
except 3.0% UDCA in the diet decreased body weight.  The relative liver weight of 
mice fed the primary BAs (CA and CDCA) at concentrations lower than 0.3% was 
not altered, but mice fed the secondary BA, DCA, at concentrations of 0.03, 0.1 and 
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0.3% in the diets, had increased relative liver weights (8-32%).  Mice fed UDCA at 
3.0% in the diet had decreased body weight (11%), but did not demonstrate altered 
relative liver weight. 
 
 
Fig 3-1  Dose response of five BAs on body weight and relative liver weight of mice treated 
with five BAs (CA, CDCA, DCA, LCA or UDCA) at concentrations of 0.01, 0.03, 0.1, 0.3 1.0 
or 3.0% in the diets for one week.  Data are presented as Mean ± S.E.M (n=5).  *P<0.05 
 
Total BA Concentrations in Serum and Liver.  As shown in Fig 3-2, only 
feeding mice high doses of BAs, including CA and CDCA at 0.3 and 1.0%, DCA and 
LCA at 0.1 and 0.3%, as well as UDCA at 0.3, 1.0, and 3.0%, increased total BA 
concentrations in serum.  Fig 3-2 surprisingly indicates that feeding CA, CDCA, DCA, 
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and LCA at all doses did not increase total BA concentrations in liver; however, 
feeding UDCA at 3% quadrupled total BA concentrations in liver.  
 
 
Fig 3-2  Dose response of five BAs on total BA concentration in the sera and livers of mice 
treated with five BAs (CA, CDCA, DCA, LCA or UDCA) at concentrations of 0.01, 0.03, 0.1, 
0.3 1.0 or 3.0% in the diets for one week.  Data are presented as Mean ± S.E.M (n=5).  
*P<0.05 
 
Individual BA Concentrations in Serum.  To determine how much 
individual BA concentrations were increased in serum after mice were fed the 
individual BAs in their diets for one week, serum was collected and analyzed for BA 
concentrations by UPLC-MS/MS.  As shown in Fig 3-3, mice fed various 
concentrations of individual BAs generally had marked increases in the fed BA and 
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its taurine conjugate, as well as a moderate increase in its metabolite.  Feeding mice 
CA dose-dependently increased CA and its secondary BA, DCA, as well as their 
taurine conjugates in sera.   However, mice fed the lowest concentration of CA 
(0.03% in the diet) did not increase CA or DCA, nor their taurine conjugates.  After 
mice were fed CA 0.1, 0.3, or 1.0% in their diets for one week, the serum CA 
concentrations increased 4-, 21-, and 42-fold, respectively.  Mice fed the two higher 
concentrations of CA (0.3% and 1.0% in the diets) had 4- and 54-fold increases in 
serum T-CA, respectively.  The secondary BA of CA, namely DCA, in sera of mice 
fed CA at 0.1, 0.3, and 1.0% in the diets increased 1.54-, 6.94-, and 16-fold, 
respectively.  Mice fed various concentrations of CA did not have alterations in the 
concentrations of CDCA, LCA, or UDCA or their taurine conjugates in sera.  
However, feeding CA decreased α-MCA and T-MCA in sera.  
Unlike the effects of CA, CDCA-feeding only increased CDCA and T-CDCA in 
sera, but not its secondary BA, LCA.  As shown in Fig 3-3, after feeding mice CDCA 
at 0.03, 0.1, and 0.3% in their diets for one week, serum CDCA increased 6-, 15-, 
and 69-fold, and serum T-CDCA increased 46-, 0.36-, and 3-fold, respectively.  
Feeding CDCA at the tested concentrations did not alter LCA concentrations in sera.  
Mice fed 0.1 and 0.3% CDCA had a decrease in serum CA concentration, whereas 
only mice fed 0.3% CDCA had a decrease in serum DCA concentration; however 
feeding 0.3% CDCA increased α-MCA in sera (about 30%). 
DCA-feeding not only increased the serum concentrations of DCA and T-DCA, 
but also increased the serum concentrations of the primary BA CA and its taurine 
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conjugate T-CA.  After mice were fed 0.03, 0.1, and 0.3% DCA for one week, the 
serum DCA concentrations increased 3-, 19-, and 73-fold, respectively.  Mice fed 0.1 
and 0.3% DCA had increases in serum concentrations of T-DCA 4- and 162-fold, CA 
1.5- and 7-fold, and T-CA 1- and 39-fold, respectively.  Mice fed DCA did not alter 
the serum concentrations of CDCA, UDCA, and MCA, except that 0.3% DCA 
increased T-CDCA, whereas 0.03 and 0.1% DCA decreased T-MCA (about 30%). 
Mice fed LCA resulted only in an increase in LCA, but not its primary BA, 
CDCA, in sera.  Mice fed LCA at 0.03, 0.1, and 0.3% in the diets increased LCA in 
sera 67-, 225-, and 782-fold, respectively. Mice fed 0.3% LCA increased T-CDCA 2-
fold.  Mice fed 0.01% LCA in the diet had an decrease in serum concentration of T-
CA, but increases in serum concentrations of DCA and UDCA.  LCA at 0.1 and 0.3% 
in the diets increased T-DCA.  Feeding mice LCA at the tested concentrations did 
not alter α-, β-, or T-MCA in the serum.  
As shown in Fig 3-3, mice fed various concentrations of UDCA at tested 
concentrations not only had increases in serum UDCA and T-UDCA, but also had 
increases in serum CDCA, LCA, and T-LCA. 
Individual BA Concentrations in Liver.  As shown in Fig 3-4, mice fed 
individual BAs had marked increases in that particular BA and its taurine conjugate 
in liver.  The liver concentrations of secondary BAs, namely DCA or LCA, were 
increased after mice were fed the primary BAs, CA or CDCA, for one week.  Mice 
fed 0.1, 0.3, and 1.0% CA had 2-4 fold increases in liver concentrations of CA and 
T-CA.  Mice fed these same concentrations of CA also increased liver DCA 
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concentrations 2-11 fold, and T-DCA 1-5 fold.  However, feeding CA did not alter the 
concentrations of LCA, UDCA, or their taurine conjugates in liver.  Feeding mice CA 
markedly decreased α-MCA, β-MCA, ω-MCA, and taurine conjugated MCAs as well. 
In addition, feeding CA also decreased HDCA, MDCA, and their taurine conjugates 
30-90%. 
As shown in Fig 3-4, feeding mice 0.03, 0.1, and 0.3% CDCA increased 
CDCA in liver 0.6-, 4-, and 17-fold, respectively.  Feeding CDCA at 0.1 and 0.3% in 
the diets also increased T-CDCA in liver 3- and 15-fold, respectively.  Feeding mice 
lower concentrations of CDCA did not increase the secondary BA, LCA, but the 
higher concentrations of CDCA (0.3% in the diet) increased LCA and T-LCA in the 
liver 2- and 4-fold, respectively. Feeding high concentrations of CDCA in the feed 
(0.1 and 0.3%) decreased CA and DCA, as well as their taurine conjugates in liver.  
Interestingly, feeding mice CDCA dose-dependently increased UDCA in the liver 
0.5-5 fold.  Feeding mice CDCA at 0.03 and 0.1% increased α-MCA 3-4 fold, 
whereas, the high dose of CDCA (0.3% in the diet) decreased other MCAs, including 
β-MCA and ω-MCA in liver.  In addition, feeding mice high concentrations of CDCA 
in the diets decreased T-α-MCA and T-β-MCA. Interestingly, feeding CDCA also 
slightly increased HDCA, MDCA, and their taurine conjugates.   
Mice fed the secondary BA DCA, not only had marked increases in DCA and T-DCA, 
but also had increases in the primary BA, CA and T-CA (Fig 3-4).  Mice fed 0.03, 0.1, 
and 0.3% DCA had increased liver DCA concentrations 1-, 3-, and 9-fold, as well as 
increased T-DCA 1-, 2-, and 14-fold, respectively.  Mice fed the highest 
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concentrations of DCA (0.3% in the diet) tended to have decreased CDCA 
concentrations in liver, with LCA unchanged.  Feeding DCA at high dosages (0.1 or 
0.3% in the diets) decreased concentrations of UDCA and T-UDCA in liver.  DCA at 
0.3% also decreased α- and β-MCA and taurine conjugated MCA in liver.  In 
addition, feeding DCA also decreased other bile acid metabolites, including HDCA, 
MDCA, and their taurine conjugates, THDCA and TMDCA, to half of the control. 
Feeding mice LCA dose-dependently increased both LCA and CDCA 
concentrations and their conjugates in liver (Fig 3-4).  Feeding LCA decreased 
taurine and glycine conjugated CA, but did not alter the concentrations of DCA and 
its conjugates in liver.  Feeding mice even low dose of LCA markedly decreased ω-
MCA and T-ω-MCA in liver.  Similar to the effects of CDCA, feeding LCA increased 
HDCA, MDCA, and their taurine conjugates. 
Feeding mice UDCA increased UDCA and T-UDCA in the livers of mice.  
Feeding mice 0.1, 0.3, 1.0, and 3.0% of UDCA increased UDCA concentration in 
liver 50-194 fold and T-UDCA 28-63 fold.  Feeding UDCA decreased CA and T-CA, 
but increased CDCA and LCA concentrations in liver.  Only feeding mice high 
concentrations of UDCA (1.0 and 3.0% in the diets) decreased T-DCA in liver.  As 
with other BAs, UDCA also decreased MCA, including α-MCA, β-MCA, and ω-MCA, 
as well as taurine conjugated MCA in liver. At the highest dose (3% in the diet), 
UDCA increased all MCAs (α-MCA, β-MCA, and ω-MCA) and their taurine 
conjugates. 
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Fig 3-3  Dose response of five BAs on individual BA concentrations in the sera of mice 
treated with five BAs (CA, CDCA, DCA, LCA or UDCA) at concentrations of 0.01, 0.03, 0.1, 
0.3 1.0 or 3.0% in the diets for one week.  Data are presented as Mean ± S.E.M (n=5).  
*P<0.05 
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Fig 3-4  Dose response of five BAs on individual BA concentrations in the livers of mice 
treated with five BAs (CA, CDCA, DCA, LCA or UDCA) at concentrations of 0.01, 0.03, 0.1, 
0.3 1.0 or 3.0% in the diets for one week.  Data are presented as Mean ± S.E.M (n=5).  
*P<0.05 
 
61 
BA composition in liver.  BA composition in the livers from control and BA-
fed mice is shown in Fig 3-5.  The predominant BA species in control mice were CA 
(CA+T-CA, 39.4%) and MCAs (MCAs+T-MCAs, 52.7%).  Feeding mice various BA-
supplemented diets at doses not higher than 1% in the diets did not alter the total 
bile acid concentrations in liver, but it altered the percentage of each fed-BA relative 
to the total BAs in liver (Fig 3-5).  The percentage of the total CA (CA +T-CA) 
relative to the total BAs in the livers of mice fed CA at 0.3% in the diet increased 
from 39.4% to 78.6% and that of the total DCA (DCA+T-DCA) increased from 2.7 to 
13.8%, whereas, the percentage of the total MCA relative to the total BAs in livers of 
mice fed 0.3% CA in the diet decreased markedly from 52.7% to 5.6%.  In addition, 
feeding mice 0.3% CA also decreased the percentage of the total CDCA (CDCA+T-
CDCA) from 1.5% to 0.9%, that of the total LCA (LCA+T-LCA) from 0.2% to 0.1%, 
that of the total UDCA (UDCA+T-UDCA) from 1.4% to 0.5%, and that of the total 6-
OH BA (MDCA+T-MDCA+HDCA+T-HDCA) from 2.0% to 0.5%. 
Fig 3-5 also shows that feeding mice CDCA at 0.3% in the diet increased the 
percentage of the total CDCA markedly from 1.5% to 30.5%.  Feeding CDCA at 
0.3% in the diet also increased the percentage of the total LCA and that of the total 
UDCA from 0.2% to 1.2%, 1.4% to 8.1%, respectively, whereas feeding CDCA at 
0.3% in the diet markedly decreased the percentage of the total CA in the liver from 
39.4% to 2.4% and that of the total DCA from 2.7% to 0.6%.  Neither feeding CDCA 
at 0.3% altered the percentage of the total MCA, nor did it alter the percentage of 
the total 6-OH BAs in mouse livers.  
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Fig 3-5. BA composition (% of total BAs) in the livers of mice fed control diet or BAs (CA, 
CDCA, DCA, LCA, or UDCA) at concentration of 0.3% in the diet for one week. 
 
Feeding DCA at 0.3% in the diet increased the percentage of the total CA 
from 39.4% to 72.2% and that of the total DCA from 2.7 to 22.1% (Fig 3-5).  
However, feeding 0.3% DCA markedly decreased the percentage of the total MCA 
from 52.7% to 4.4%.  Feeding DCA also slightly decreased the percentage of the 
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total CDCA, the total LCA, the total UDCA,  and the total 6-OH BAs, from 1.5% to 
0.5%, 0.2 to 0.03%, 1.4 to 0.3%, and 2.0 to 0.6%, respectively.   
Feeding LCA at 0.3% in the diet increased the percentage of the total LCA 
from 0.2 to 6.4%, the percentage of the total CDCA from 1.5 to 11.5%, that of the 
UDCA from 1.4 to 2.7%, and that of the total 6-OH BAs from 2.0 to 33.5% (Fig 3-5).  
However, feeding 0.3% LCA markedly decreased the percentage of the total CA 
from 39.4% to 11.2 and the percentage of the total MCA from 52.7% to 31.9%.  
Feeding LCA had little effect on the percentage of the total DCA.  
Feeding UDCA at 0.3% in the diet markedly increased the percentage of the 
total UDCA from 1.4 to 79.4% (Fig 3-5).  However, feeding UDCA at 0.3% in the diet 
markedly decreased the percentage of the total CA and that of the total MCA from 
39.4 to 2.7% and 52.7 to 7.20%, respectively.  Feeding 0.3% UDCA slightly 
increased the percentage of the total CDCA from 1.5 to 3.2%, that of the total LCA 
from 0.2 to 1.4%, and that of the total 6-OH BAs from 2.0 to 4.8%. 
Liver Histopathology.  A representative histological section of liver from a 
control mouse and from mice fed each of the five BAs is shown in Fig 3-6.  At high 
concentrations in the diets (CA at 1.0%, CDCA and LCA at 0.3%, or UDCA at 3.0%), 
none of the BAs caused liver necrosis.  However, feeding DCA at 0.3%, or LCA at 
0.3% in the diets caused random cell swelling and random single cell death.  
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Fig 3-6  Representative microphotographs of hematoxylin and eosin (H & E) stained liver 
sections from control mice and mice fed individual BA supplemented diets for one week 
(Magnification X400).  Arrows indicate focal necrosis or single cell death. 
 
Serum ALT.  To determine the doses of each individual BAs that produce 
hepatotoxicity, serum ALT activity was quantified.  As shown in fig 7, feeding mice 
the primary BAs, CA and CDCA, at concentrations of 0.3 or 1.0% in the diets 
increased serum ALT activity.  However, feeding CA and CDCA did not increase 
serum ALT activity at either 0.03 or 0.1% in the diets.  The serum ALT activity level 
was increased after feeding DCA at a concentration as low as 0.1% in the diet.  
Feeding LCA at concentrations of 0.03, 0.1, and 0.3% in the diets increased serum 
ALT activity.  However, there are no increases in serum ALT activity after feeding 
mice UDCA at any concentrations in the diets tested.  
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Fig 3-7  Dose response of five BAs on serum ALT after mice were fed various BAs 
supplemented diets for one week.  Data are presented as mean ± SEM (each group, n =5 
mice). Asterisks represent statistically significant differences (p< 0.05) between control and 
treatment groups 
 
3.4  Discussion   
There has been a resurgence in BA research since BAs have been found to 
be important signaling molecules regulating not only BA homeostasis, but also the 
homeostasis of cholesterol, glucose, and energy (Makishima et al., 1999; Parks et 
al., 1999; Redinger, 2003; Katsuma et al., 2005; Watanabe et al., 2006; Lefebvre et 
al., 2009).  To determine the physiological functions of individual BAs, diets 
supplemented with various individual BAs at either 0.5 or 1.0% in the diets are often 
fed to mice (Zollner et al., 2003a; Miyata et al., 2006).  However, it has been known 
that increased concentrations of BAs in liver can result in inflammation, cell death, 
and decreased liver function.  The present study indicates that at concentrations of 
0.3% or above in the diet, all BAs, except for UDCA, produced hepatotoxicity 
indicated by increases in serum ALT activity levels and increases in serum BA 
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concdentrations.  Even though, UDCA at 0.3, 1.0, and 3.0% in the diet did not cause 
an increase in serum ALT activity levels, UDCA at these concentrations in the diet 
increased the total serum BA concentration and the secondary BA LCA, indicating a 
possible hepatotoxicity.   
A novel finding in this study was that feeding exogenous BAs at doses which 
produce hepatotoxicity does not, as expected, increase the total liver BA 
concentration in mice.  However, feeding exogenous BAs altered the BA 
composition in liver.  Thus, it appears to be altered BA composition, rather than 
increases in total liver BA concentration, that is responsible for hepatotoxicity of the 
fed-BA, including CA, CDCA, DCA, and LCA.   
Even though there are no reports in which the relative hepatotoxicity of the 
five BAs (CA, CDCA, DCA, LCA, and UDCA) were compared in the same study, it 
has been generalized that LCA is the most toxic BA, followed by DCA, CDCA, and 
CA, whereas, UDCA has hepatoprotective effects and is used for the treatment of 
cholestatic liver diseases (Copaci et al., 2005).  In the present study, the relative 
hepatotoxicity of the five BAs were compared and the lowest hepatotoxic doses 
were determined based on the serum ALT activity, which is a traditional biochemical 
index of liver function and is used clinically for early diagnosis of liver injury.  
According to the increases in serum ALT activity, the lowest dietary concentration of 
CA and CDCA that was hepatotoxic in the present study was 0.3%, whereas it was 
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0.1% for DCA, and 0.03% for LCA.  However, UDCA at any dose used in the 
present study did not cause an increase in serum ALT activity. 
Compared to the conventional serum biochemical test, namely serum ALT, 
serum BA (SBA) concentration is a more sensitive and accurate indicator of liver 
function (Azer et al., 1997; Ambros-Rudolph et al., 2007).  For example, in liver 
cirrhosis, the serum ALT level may be normal, however, the SBA concentration 
increases (Mannes et al., 1982).  Moreover, SBA is used for early diagnosis of 
obstetric cholestasis, which can be lethal for the fetus.  In some cases of obstetric 
cholestasis, there are no obvious symptoms, nor are there increases in serum ALT, 
whereas an increase in SBA concentrations usually is the only index for the 
diagnosis of cholestasis during pregnancy (Azer et al., 1997; Walker et al., 2002; 
Ambros-Rudolph et al., 2007).  Thus, in the present study, SBA concentration is 
used as a second indicator of liver function.  According to the increases in the total 
serum bile acid (TSBA) concentration (Fig 3-2), the lowest hepatotoxic doses for CA, 
CDCA, and DCA are the same as those determined based on the increases in 
serum ALT activity, that is, 0.3% in the diet for CA and CDCA, and 0.1% for DCA.  
However, the hepatotoxic doses determined according to the TSBA concentrations 
for LCA and UDCA are 0.1% and 0.3% respectively, which are different from those 
determined by serum ALT levels.  The difference may be explained by the following 
evidence.  1) The BA composition in serum is more important than TSBAs in 
predicting liver dysfunction.  Individual serum BAs, especially increases in 
hydrophobic BAs, such as LCA, are more sensitive and specific as early predictors 
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of liver injury (Azer et al., 1997).  Even though feeding mice 0.03% LCA did not 
increase the TSBA concentration, the serum LCA concentration was increased more 
than five times (Fig 3).  The increase in serum LCA is comparable to the increase in 
serum ALT level in mice fed 0.03% LCA.  Accordingly, in the present study, the 
lowest hepatotoxic dose for LCA determined by increases in ALT level and serum 
LCA concentration is 0.03% in the diet.  2)  Feeding UDCA at 0.3, 1.0 and 3.0% 
increased not only the TSBA, but also the concentration of LCA, suggesting liver 
injury.  UDCA is clinically used as a therapeutic drug for various liver diseases, 
including primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) 
(Crosignani et al., 1991; Hofmann, 1994; Sinakos et al., 2010).  Administration of 
UDCA to patients with PBC increases both the TSBA concentration and the serum 
LCA concentration, however, it still improved all biochemical indices of liver function 
in PBC patients (Crosignani et al., 1991).  In addition, UDCA is known to have 
opposite effects to that of LCA. For example, LCA repressed LPS-induced 
production of TNFα, whereas, UDCA boosts LPS-induced production of TNFα in the 
THP-TGR5 cell line (Kawamata et al., 2003).  UDCA has cytoprotective effects, 
whereas, LCA is cytotoxic.  Direct evidence that UDCA is able to counteract the 
toxicity of LCA was shown in an in vitro study which demonstrated that UDCA can 
not only protect against the cholestatic effects of LCA, but also partially reversed the 
cholestasis caused by LCA (Milkiewicz et al., 1999).  Moreover, the hepatotoxicity of 
UDCA is species dependent.  In species that do not have the ability to sulfate and 
thus detoxify LCA, such as the rhesus monkey, feeding UDCA is quite toxic, 
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however, in humans and rodents, UDCA is relatively non-toxic (Bazzoli et al., 1982).  
Accordingly, even though the increases in the concentrations of TSBA and LCA in 
the sera of mice fed UDCA at 0.3% in the diet or above, increases the possibility of 
hepatotoxicity of UDCA, we could not rule out the possibility that the therapeutic 
effects of UDCA can counteract the toxic effects of its metabolite LCA.  Collectively, 
the data in the present study can only conclude that 0.1% in the diet is a non-
hepatotoxic dose for UDCA, however, data in the present study are not sufficient to 
make an absolute conclusion that 0.3% in the diet is a hepatotoxic dose for UDCA.  
More data should be generated in regarding to whether the therapeutic effects of 
UDCA under certain dose range can counteract its metabolite LCA before final 
conclusions are drawn on hepatotoxic doses of UDCA. 
The hepatotoxic doses of the four BAs determined in the present study 
appears to be different from some reports in the literature that indicate that 0.5 or 
1.0% CA or CDCA in the diets are not hepatotoxic in mice (Sinal et al., 2000; Guo et 
al., 2003; Yamagata et al., 2004; Miyata et al., 2005).  However, consistent with the 
present findings, other reports indicate that CA at concentrations higher than 0.1% in 
the diet are hepatotoxic to mice (Fickert et al., 2001; Wang et al., 2003a), and others 
have reported that both DCA and LCA at 0.5 and 1.0% are toxic to rats (Delzenne et 
al., 1992).  The reasons for these differences may root in differences in duration 
and/or cholesterol or other chemicals (Wang et al., 2003c) added with BAs in the 
diets, as well as different criteria for hepatotoxicity.  In addition, based on our 
experience, the experimental procedures employed (detailed in methods), including 
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thoroughly mixing the finely ground BA with fine powdered diet, replacing the cages 
with clean ones right before feeding mice the BA-supplemented diet, and replacing 
the feeding bowls and cages with clean ones every day during the duration of the 
feeding process, may be critical in ensuring the final experimental results. 
An increase in total BA concentration in liver is thought to be a major feature 
of cholestatic liver diseases.  High concentrations of BAs in cholestatic liver cause 
liver inflammation and apoptosis or necrosis (Krell and Enderle, 1993; Kodali et al., 
2006).  Thus, it is expected that feeding mice hepatotoxic doses of BAs will increase 
the total BA concentrations in liver.  However, the data in the present study 
demonstrated that feeding mice BAs, including CA, CDCA, DCA, and LCA, at 
hepatotoxic doses, did not increase the total BA concentration in liver, rather it 
markedly altered the BA composition, featured by increases in the relative 
percentage of the fed-BA and its corresponding metabolite, as well as a decrease in 
the percentage of the primary BA: β-MCA or CA (Fig. 3-5).  This suggests that the 
balance between different BA species in liver is critical for maintaining normal liver 
function.  An imbalance between different BA species appears to cause BA-induced 
hepatotoxicity.  There are several possible explanations for the contribution of the 
imbalanced liver BA composition to the hepatotoxicity of the fed-BA: 1). Increases in 
hydrophobicity of BA pool: The fed-BA species are more hydrophobic than MCAs in 
mice.  Based on the hydrophobicity index (HI) of individual BA, the relative 
hydrophobicity of different BA species are as follows: LCA>DCA>CDCA (HI: 
0.5) >CA (HI: 0.1) >HDCA (HI: –0.30) >UDCA (HI: about –0.4) >MCAs (HI: about –
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0.7) (Heuman, 1989).  An increased percentage of the fed-hydrophobic-BA (CA, 
CDCA, DCA, or LCA) together with depletion of the hydrophilic MCAs will increase 
hydrophobicity of the BA pool, causing hepatobiliary injury (Attili et al., 1986; Becker 
et al., 2007).  In certain instance, such as CDCA-feeding, the percentage of MCAs 
was not affected because CDCA can be easily hydroxylated at the 6β position to 
produce MCAs in rodents.  However, the other primary BA in mice, a less 
hydrophobic CA (HI: 0.1) was replaced by CDCA (HI: 0.5) (Fig 5).  Thus, CDCA-
feeding can increase the hydrophobicity of BA pool which may also play a role in 
CDCA-induced hepatotoxicity.  2) Effects of the metabolites on the hepatotoxicity of 
the fed-BA: It is well established that the primary BAs, CA and CDCA, can be 
dehydroxylated at the 7α position by the flora in the intestine to produce the 
secondary BAs, DCA and LCA respectively (Iwamura, 1982).  Meanwhile, the 
secondary BAs, DCA and LCA can be re-hydroxylated at the 7-postion in the liver to 
produce the primary BAs CA and CDCA, respectively (Greim et al., 1973b).  The 
increased percentage of the secondary BAs after feeding mice the primary BAs, at 
hepatotoxic doses may contribute to the hepatoxicity of the parent compounds, 
whereas, the increased primary BA species (CA or CDCA) after feeding mice the 
secondary BA species (DCA or LCA) may account for mild toxic effects of the 
secondary BAs.  In addition to CDCA, other notable metabolites of LCA were MDCA 
and HDCA which are much more hydrophilic than LCA and CDCA.  The toxicity of 
LCA is limited through biotransformation into CDCA, MDCA and HDCA.  3) Possible 
contribution of altered cholesterol levels:  The β-MCA is more effective than the fed-
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BAs in preventing cholesterol saturation in bile (Wang and Tazuma, 2002; Wang et 
al., 2003a).  Replacement of the hydrophilic MCAs with the fed-hydrophobic BAs 
(CA, CDCA, DCA or LCA, but not UDCA) will likely increase the cholesterol 
absorption from the intestine (Montet et al., 1982).  Furthermore, feeding BA also 
inhibits both the mRNA expression and the enzyme activity of cholesterol 7α-
hydroxylase (Cyp7a1) (Chiang, 2009), the rate-limiting enzyme in the classic BA 
biosynthesis pathway, resulting in cholesterol accumulation in liver.  Consequently, 
the increased intestinal absorption of cholesterol and the decreased catabolism of 
cholesterol after feeding the hydrophobic BAs will result in cholesterol accumulation 
in liver, as a result, the balance between cholesterol and BAs is also likely to be 
disturbed by BA-feeding.  The imbalance between cholesterol and BAs will produce 
so-called “toxic bile” which may damage the hepatobiliary structure (Trauner et al., 
2008). 
In conclusion, the present study indicates that it is the imbalanced BA 
composition in liver, but not the increases in the total liver BA concentration per se, 
that exerts major influences on the hepatotoxicity of each fed-BA.  In addition, the 
present study also demonstrates that the lowest hepatotoxic dose of each BA is as 
follows, CA and CDCA at 0.3% in the diet, DCA at 0.1%, and LCA at 0.03% in the 
diet. UDCA at 0.3% in the diet or above might be hepatotoxic.  Moreover, the 
present data indicate that the non-hepatotoxic dose of each fed-BA is 0.1% in the 
diet for CA, CDCA, and UDCA, 0.03% for DCA, and 0.01% for LCA. 
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CHAPTER 4 
ADAPTIVE GENE EXPRESSION IN RESPONSE TO  
ALTERED BILE ACID COMPOSITION IN MICE FED 
NON-HEPATOTOXIC DOSES AND HEPATOTOXIC DOSES OF BILE ACIDS 
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4.1  Abstract 
BAs can regulate their own biosynthesis and transport at the transcriptional 
level via activation of FXR.  Our previous study has shown that feeding mice BAs at 
either non-hepatotoxic or hepatotoxic doses did not increase the total liver BA 
concentration, suggesting adaptation in the expression of genes involved in BA 
biosynthesis and transport.  Thus, the purpose of this study was to investigate the 
expression of genes involved in BA homeostasis and the possible roles of the 
hepatic and the ileum FXR signaling pathways in regulating these genes to 
maintaining the total BA concentrations in the livers of mice fed different doses of 
BAs.  Mice were fed five individual BAs, including CA, CDCA, DCA, LCA, and UDCA, 
at various concentrations (0.01, 0.03, 0.1, 0.3, 1.0, or 3.0%) in the diet for one week.  
Messenger RNAs of genes involved in BA homeostasis were quantified using 
QuantiGene Plex assays.  FXR in liver was activated by all the BAs and at all doses, 
as indicated by induction of SHP mRNA in the livers.  Correspondingly, Cyp7a1 
mRNA was reduced by all doses of BAs.  In contrast, the FXR in the ileum was 
activated by CA and DCA at all doses, as evidenced by induction of Fgf15 mRNA, 
whereas, only at hepatotoxic doses did CDCA and LCA activate the ileum FXR.  
Inversely to the activation pattern of the FXR-Fgf15 signaling pathway in the ileum, 
Cyp8b1 was suppressed by low-non-hepatotoxic doses of CA and DCA, but not by 
CDCA and LCA at same doses.  In contrast, the mRNA of the major BA uptake 
transporter Ntcp was reduced only by high-hepatotoxic doses of the five BAs, but 
not by low-non-hepatotoxic doses of BAs.  In addition, the cholesterol transporter 
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Abcg5/g8 was induced by all doses of the five BAs, whereas, the phospholipid 
translocator Mdr2 was induced only by high-hepatotoxic doses of the five BAs.  In 
conclusion, the hepatic FXR-SHP signaling may mediate suppression of Cyp7a1 by 
all doses BAs, whereas, the ileum FXR-Fgf15 signaling may mediate suppression of 
Cyp8b1 by CA and DCA at all doses and by CDCA and LCA at hepatotoxic doses. 
In addition, suppression of Cyp7a1 by low-non-hepatotoxic doses of BAs is sufficient 
adaptation to maintain the total liver BA concentration, whereas, suppression of both 
Cyp7a1 and the major BA uptake transporter Ntcp contribute to the maintenance of 
the total liver BA concentration in mice fed BAs at hepatotoxic doses. 
4.2  Introduction:   
BAs play important roles in various physiological processes, including 
facilitating absorption of lipids and elimination of cholesterol, as well as acting as 
hormones regulating the homeostasis of BAs, cholesterol, and glucose (Lefebvre et 
al., 2009).  However, BAs, as biological detergents, are also toxic. Thus the levels of 
BAs in liver must be tightly regulated.  The regulation is usually through manipulation 
of biosynthesis, transport and detoxification of BAs.  
The biosynthesis of BAs occurs mainly in liver.  Two major biosynthesis 
pathways have been identified, namely, the classic pathway initiated by the enzyme 
Cyp7a1 (cholesterol 7α-hydroxylase) in the endoplasmic reticulum of the hepatocyte 
(Russell and Setchell, 1992), and the alternative pathway, initiated by the enzyme 
Cyp27a1 (sterol 27-hydroxylase) in the mitochondria of a variety of tissues (Russell 
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and Setchell, 1992; Bjorkhem et al., 1999).  In mammals, the main products of the 
classic pathway are CA and CDCA.  The enzyme Cyp8b1 (sterol 12-hydroxylase) is 
critical in determining the ratio between CA and CDCA (Pandak et al., 2001).  Mice 
lacking Cyp8b1 do not synthesize CA (Li-Hawkins et al., 2002).  With the presence 
of Cyp8b1, the 7α-hydroxylated intermediates from the upstream reactions in the 
classic BA biosynthesis pathway can be used to form a 12-OH BA, CA, whereas, 
without Cyp8b1, the 7α-hydroxylated intermediate will be used to form the end 
product CDCA, which is a non-12-OH BA.  The predominant end product from the 
alternative pathway is thought to be CDCA.  The oxysterol 7α-hydroxylase (Cyp7b1) 
is employed in the alternative pathway to catalyze 27α-hydroxylated intermediate 
from the upstream of the alternative BA biosynthesis pathway to produce 7α,27α-di 
hydroxylated intermediates (Bjorkhem, 1992).  It is proposed that the 7α-
hydroxylated intermediates of the alternative pathway can also be 12-hydroxylated 
by Cyp8b1 to form the end product CA, because Cyp8b1 deficiency causes 
complete depletion of CA (Li-Hawkins et al., 2002).  In rodents, CDCA can be 6β-
hydroxylated to form α-MCA, from which the dominant muri-BA, β-MCA, is derived 
(Botham and Boyd, 1983).  Thus, in rodents, CA and β-MCA, instead of CDCA, are 
the primary BAs.  In rodents, the alternative pathway is thought to contribute to a 
substantial fraction of the total BA biosynthesis under physiological conditions 
(Vlahcevic et al., 1997). 
To ensure their physiological functions, normal enterohepatic circulation 
(EHC) of BAs is essential.  Two main processes are involved in EHC: liver secretion 
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and intestinal reabsorption of BAs.  Multiple active transport systems in both liver 
and intestine are involved in the EHC of BAs.  The hepatocytes are polarized 
epithelia with the sinusoid membrane facing the blood and the canalicular 
membrane facing the bile.  After BAs are synthesized in the hepatocytes, the glycine 
or taurine conjugated monovalent BAs are actively pumped by the BA-efflux pump, 
Bsep,  into the canaliculi (Gerloff et al., 1998).  The divalent BAs, such as sulfated 
LCA, are transported actively by the multidrug resistance associated protein Mrp2 
into bile (Muller and Jansen, 1997; Takikawa, 2002).  BAs in the canaliculi then go 
through various biliary ducts and are finally stored in the gallbladder.  Upon each 
meal, BAs are released from the gallbladder into the intestine where BAs emulsify 
dietary lipids to facilitate their absorption.  About 95% of BAs released into the 
intestine are reabsorbed.  The Asbt (Apical sodium dependent bile salt transporter) 
on the apical membrane of the enterocytes takes up BAs from the lumen of the 
intestine and transfers BAs into the cytosol of the enterocytes.  Inside the cytosol, 
the Ibabp (ileum BA binding protein) is thought to bind BAs and transfer the BAs 
across the cytosol to the basolateral membrane of the enterocytes, where the efflux 
transporter Ostα/β pumps BAs into the portal blood.  BAs in the portal vein 
eventually return to the liver where they are taken up by the sodium dependent BA 
transporter Ntcp and sodium independent transporters Oatps.  The recycled BAs 
together with the de novo synthesized BAs then go through another EHC cycle 
(Alrefai and Gill, 2007). 
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Biliary secretion of BAs must be accompanied with proportional lipid secretion, 
so that the mixed micelles composed of BAs, cholesterol and phospholipids can 
form to protect the hepatobiliary system from the toxicity of free BAs and to prevent 
the deposit of cholesterol in the bile.  Without the lipid components, simple micelles 
composed solely of BAs can form, which can damage the membranes of the biliary 
tract (Hofmann and Hagey, 2008).  Various lipid translocators in the canalicular 
membrane of hepatocytes are involved in lipid excretion into bile: the Abcg5/g8 
mediates the translocation of cholesterol; the Mdr2 flops the phospholipid into the 
bile, whereas the Atp8b1 translocates the amino-phospholipids from the outer leaflet 
to the inner leaflet of the canalicular membrane to maintain the asymmetric 
distribution of phospholipids in the membrane (Eppens et al., 2001; Ujhazy et al., 
2001). 
It has been thought that excessive BAs can activate the nuclear receptor FXR 
to regulate the homeostasis of BAs (Makishima et al., 1999; Parks et al., 1999; 
Wang et al., 1999).  FXR negatively regulates BA biosynthesis enzymes Cyp7a1 
and Cyp8b1 (Goodwin et al., 2000; Chiang, 2002), as well as hepatic uptake 
transporter Ntcp (Denson et al., 2001), while positively regulates the expression of 
Bsep (Ananthanarayanan et al., 2001), and Ostα/β (Boyer et al., 2006).  In 2005, an 
intestinal signaling pathway mediated by ileum FXR-Fgf15 was identified.  The 
intestinal FXR can be activated by CA, causing increased expression of Fgf15, 
which travels via the portal vein to the liver where it activates the cell surface 
receptor FGFR4, causing a decrease in expression of Cyp7a1 mRNA (Inagaki et al., 
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2005; Kim et al., 2007). Our previous study (Chapter 3) determined the non-
hepatotoxic and hepatotoxic doses of individual BAs (see summary in Table 4-1) 
and showed that feeding mice BAs (CA, CDCA, DCA, or LCA) at hepatotoxic doses 
did not increase the total BA concentration in liver, but it disturbed the liver BA 
composition, featured by a depletion of the primary BAs (MCAs or CA) and an 
enrichment of the fed-BA.  These findings suggest a wide range of adaptations in BA 
biosynthesis and transport.  Therefore, in this present study, we investigated the 
adaptive changes in the expression of genes involved in BA homeostasis in mice fed 
either low-non-hepatotoxic doses or high-hepatotoxic doses of individual BAs, as 
well as the possible roles of the BA receptor FXR in the regulation of these genes.   
 
 
 
 
 
 
 
 
 
 
Table 4-1.  List of doses of individual bile acid used in the 
present study.  
  
Non-hepatotoxic doses 
(W/W% in the diet) 
Hepatotoxic doses  
(W/W% in the diet) 
CA 0.03 and 0.10% 0.30 and 1.0% 
CDCA 0.03 and 0.10% 0.30% 
DCA 0.03% 0.10 and 0.30% 
LCA 0.01% 0.03, 0.10 and 0.30% 
UDCA 0.10% 0.30 and 1.0% 
80 
4.3  Results 
Effect of feeding BAs at non-hepatotoxic doses on total liver BA 
concentration and liver BA composition.  As shown in Fig 4-1, feeding each BA 
at low-non-hepatotoxic doses (CA, CDCA, and DCA at 0.03% in the diets, LCA at 
0.01% in the diet, and UDCA at 0.1% in the diet) did not increase the total liver BA 
concentration, rather, the total liver BA concentration after non-hepatotoxic doses of 
BA-feeding tends to decrease; however the liver BA composition was slightly altered.  
Feeding of CA and DCA resulted in similar changes in liver BA composition.  More 
specifically, feeding CA or DCA at 0.03% in the diet increased the percentage of the 
total CA (CA+T-CA) from 39.4% to about 51%, and decreased the total MCAs from 
52.7% to around 38% of the total liver BAs.  Interestingly, feeding both CA and DCA 
at 0.03% in the diet increased the percentage of the total DCA (DCA+T-DCA) from 
2.7 to about 5-8%.  There are no effects of feeding of CA or DCA at 0.03% in the 
diets on the percentage of other BA species.  Feeding CDCA at 0.03% in the diet 
not only increased the total CDCA (CDCA+T-CDCA) from 1.5% to 4.0% relative to 
the total liver BAs, but also slightly increased the total MCAs (MCAs+T-MCAs) and 
the total 6-OH BAs (HDCA+T-HDCA+MDCA+T-MDCA) from 52.7 to 66.3% and 2.0 
to 4.6% respectively.  Feeding CDCA decreased the percentage of total CA from 
39.4 to 19.3% relative to the total liver BAs.  Feeding 0.01% LCA in the diet did not 
increase the percentage of the total LCA, neither did it increase the percentage of 
the total MCAs.  However, feeding 0.01% LCA in the diet increased the percentage 
of its metabolites, CDCA and 6-OH BAs (MDCA plus HDCA) from 1.5 to 4.0% and 
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2.0 to 4.6%, respectively, of the total liver BAs.  Feeding LCA also decreased slightly 
the percentage of total CA from 39.4 to 33.0%.  
  
 
Fig 4-1  Total BA concentrations and BA composition (% of total BAs) in the livers of mice 
fed control diet or diets supplemented with BAs (CA, CDCA, DCA, LCA, or UDCA) at non-
hepatotoxic doses for one week. 
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Feeding UDCA at 0.1% in the diet increased the percentage of the total LCA, 
the total UDCA, and the 6-OH BAs from 0.2 to 1.1%, 1.4 to 50.2%,  and from 2.0 to 
8.3%, respectively,  whereas, feeding UDCA decreased the percentage of the total 
CA and the total MCAs from 39.4 to 12.9 % and 52.7 to 22.3%, respectively.  
Effect of BA feeding on mRNA expression of BA-biosynthesis enzymes 
in liver  To investigate the effects of various individual BAs on mRNA expression of 
BA-biosynthesis enzymes, the mRNA of Cyp7a1, 8b1, 27a1 and 7b1, were 
quantified.  As expected, after feeding mice various BAs for one week, Cyp7a1 
mRNA expression was reduced markedly (about 70-99%) by all fed-BAs at all doses 
(Fig 4-2).  The suppression of Cyp7a1 by feeding of the 12-OH-BAs (CA and DCA) 
was the maximum (about 95%) even at the lowest non-hepatotoxic doses (0.03% in 
the diets), whereas, suppression of Cyp7a1 by feeding the non-12-OH BAs (CDCA 
and LCA) had an obvious dose-dependent response.  Feeding the two non-12-OH 
BAs at the lowest dose suppressed the mRNA expression of Cyp7a1 about 70%, 
with doses increasing, the suppression reached the maximum at 96%.  Feeding 
UDCA at various doses suppressed the mRNA expression of Cyp7a1 93-100%.  
The mRNA expression of Cyp8b1 was also down-regulated by feeding BAs, but the 
reduction required higher doses of BAs.  The two 12-OH BAs decreased Cyp8b1 at 
all doses tested.  However, unlike their effects on Cyp7a1 expression, the non-12-
OH BAs suppressed Cyp8b1 mRNA expression only at high hepatotoxic doses. 
Specifically,  CDCA and LCA at 0.3% in the diets, and UDCA at 0.3, 1.0, and 3.0% 
in the diets, decreased Cyp8b1 mRNA levels.   
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Fig 4-2  Messenger RNA expression of genes involved in BA biosynthesis in livers of mice 
treated with five BAs (CA, CDCA, DCA, LCA, or UDCA) at concentrations of 0.01, 0.03, 0.1, 
0.3, 1.0, or 3.0% in the diets.  Data are presented as Mean ± S.E.M (n=5).  *P<0.05 
 
BA feeding had relatively minor effects on Cyp27a1 mRNA expression (Fig 4-
2.).  Feeding CA at all doses decreased Cyp27a1 mRNA expression 12-19%.  
Feeding CDCA at the lowest (0.03% in the diet) and highest dose (0.3% in the diet) 
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decreased Cyp27a1 mRNA expression about 15%.  Feeding DCA at 0.03 and 0.1% 
decreased Cyp27a1 mRNA expression 15% and 60%, respectively.  The effect of 
BA feeding on Cyp7b1 mRNA was quite different than that on Cyp7a1.  Whereas, 
BA feeding almost eliminated Cyp7a1 mRNA expression, it tended to increase 
Cyp7b1 mRNA expression.  However, the highest doses of DCA (0.3% in the diet) 
and UDCA (3.0% in the diet) markedly decreased Cyp7b1 mRNA. 
Effect of BA feeding on mRNA expression of hepatic uptake 
transporters in liver  As shown in Fig 4-3, after feeding non-hepatotoxic doses of 
BAs, Ntcp mRNA expression was not altered, however, at higher and hepatotoxic 
doses, Ntcp mRNA expression was decreased.  Specifically, CA and DCA (0.3 or 
1% in the diet), the highest concentration of LCA (0.3% in the diet), and two 
intermediate concentrations of UDCA in the feed (0.3 and 1.0) produced rather small 
decreases (12-30%) in the expression of Ntcp.  CDCA did not alter Ntcp mRNA 
expression at any dose. 
The Oatps (Oatp1a1, 1a4, and 1b2) are considered to have a less important 
role in BA uptake into liver than Ntcp.  As shown in Fig 4-3, Oatp1a1 mRNA was not 
altered markedly by BA feeding, except for the highest doses of DCA (0.3% in the 
diet) and UDCA (3.0% in the diet), which decreased Oatp1a1.  Oatp1a4 mRNA was 
also not altered markedly by BA feeding, with the exception of the highest dose of 
UDCA (3.0% in the diet) that increased Oatp1a4 nearly 10-fold.  Oatp1b2 mRNA is 
specifically, if not exclusively, expressed in liver; feeding BAs produced only small 
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increases in Oatp1b2 mRNA expression, except for the highest concentration of 
DCA, which decreased it about 30%.   
 
 
Fig 4-3  Messenger RNA expression of genes involved in BA uptake in livers of mice treated 
with five BAs (CA, CDCA, DCA, LCA, or UDCA) at concentrations of 0.01, 0.03, 0.1, 0.3, 1.0, 
or 3.0% in the diets.  Data are presented as Mean ± S.E.M (n=5).  *P<0.05 
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Effect of BA feeding on mRNA expression of hepatic efflux transporters 
located on the canalicular membrane of hepatocytes  The effects of BA feeding 
on Bsep mRNA levels are shown in Fig 4-4.  CA was the only BA that increased 
Bsep mRNA (35%), and this occurred only with the high-hepatotoxic doses of CA 
(0.3 and 1.0% in the diets).  CDCA and LCA produced small (25-35%), but 
statistically significant decreases in Bsep mRNA.  The three lower concentrations of 
UDCA also decreased Bsep mRNA. 
As shown in Fig 4-4, BA feeding had relatively minor effects on Mrp2 mRNA 
expression.  
After feeding mice various BAs, there were very little changes in Atp8b1 
expression, except that the largest doses of UDCA (3.0% in the diet) decreased 
Atp8b1 expression about 30% (Fig 4-4).  
Feeding the five BAs at all doses increased Abcg5 mRNA expression (Fig 4-
4).  More specifically, CA, DCA, and UDCA increased Abcg5 mRNA in a dose-
dependent manner.  Similarly, Abcg8 mRNA was increased by feeding all BAs.  
Collectively, these studies demonstrate that Abcg5 and Abcg8 are up-regulated by 
all five BAs at both low-non-hepatotoxic doses and high-hepatotoxic doses. 
As shown in Fig 4-4, feeding of all BAs at high-Hepatotoxic doses produced 
small increases in Mdr2 mRNA expression in liver. 
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Fig 4-4  Messenger RNA expression of efflux transporters on canalicular surfaces of 
hepatocytes in mice treated with five BAs (CA, CDCA, DCA, LCA, or UDCA) at 
concentrations of 0.01, 0.03, 0.1, 0.3, 1.0, or 3.0% in the diets.  Data are presented as Mean 
± S.E.M (n=5).  *P<0.05 
 
Effect of BA feeding on mRNA expression of hepatic efflux transporters 
located on the sinusoidal membrane of hepatocytes or basolateral membrane 
of cholangiocytes in liver.  As shown in Fig 4-5, feeding BAs (CA, CDCA, and, 
LCA) produced a small (about 20%) but statistically significant increase in Mrp3 
mRNA.  Feeding BAs had only a minor effect on the expression of Mrp4, as only 
feeding 3.0% UDCA in the diet increased Mrp4 mRNA.  
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Fig 4-5  Messenger RNA expression of efflux transporters on sinusoid surfaces of 
hepatocytes in mice treated with five BAs (CA, CDCA, DCA, LCA, or UDCA) at 
concentrations of 0.01, 0.03, 0.1, 0.3, 1.0, or 3.0% in the diets.  Data are presented as Mean 
± S.E.M (n=5).  *P<0.05 
 
As shown in Fig S4-1, the expression of Ostα/β in liver is rather low. Ostα 
mRNA was increased by feeding each of the five BAs.  However, Ostβ mRNA was 
increased dose-dependently only by CA and DCA, as well as the highest doses of 
UDCA.  But Ostβ was not altered by either CDCA or LCA.  
Effect of BA feeding on mRNA expression of nuclear receptors and their 
target genes in liver.  As shown in Fig 4-6, FXR mRNA was not altered by any of 
the BAs, except for the highest dose of UDCA, which increased FXR mRNA.  In 
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contrast, the FXR-target gene SHP was increased by all BAs and at all doses tested, 
suggesting that FXR is activated by all five BAs.   
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Fig 4-6  Messenger RNA expression of FXR and its target gene SHP in livers of mice 
treated with five BAs (CA, CDCA, DCA, LCA, or UDCA) at concentrations of 0.01, 0.03, 0.1, 
0.3, 1.0, or 3.0% in the diets.  Data are presented as Mean ± S.E.M (n=5).  *P<0.05 
 
PXR mRNA was only increased by feeding high concentrations of BAs (Fig 
S4-2), and its target gene Cyp3a11 mRNA was not increased by any of the BAs.  
Even though there are increases in the mRNA expression of Car (20-35% in the 
diets) in mice fed CA at 0.03 and 0.3%, CDCA at 0.3%, DCA and LCA at 0.1% in the 
diet, there are no corresponding increases in the mRNA expression of its target 
gene Cyp2b10.  Only feeding of UDCA at 3.0% increased both Car about 130% and 
its target gene Cyp2b10 about 8 fold.  Both Nrf2 mRNA and its target gene Nqo1 
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were increased by high concentrations of BAs, including CA at 0.3 and 1.0%, and 
DCA at 0.3% in the diets.  UDCA at the highest concentration (3.0%) in the diet also 
increased mRNA expression of Nrf2 and its target gene Nqo1 (Fig S4-2).  
Surprisingly, only feeding CDCA at the lowest dose (0.03% in the diet) increased 
both Nrf2 and NqO1 mRNA expression. 
Effects of feeding of individual BAs on mRNA expression of FXR and its 
target genes in ileum  As shown in Fig 4-7, feeding mice BAs did not alter the 
mRNA expression of FXR in the ileum.  However, feeding CA and DCA dose-
dependently increased the FXR-target genes SHP and Fgf15 mRNA expression.  
Conversely, only the highest concentrations of CDCA in the diet increased SHP and 
Fgf15 mRNA, whereas LCA at the highest concentration and UDCA at all 
concentrations tested increased Fgf15 mRNA but not SHP mRNA in the ileum.  
Effect of feeding individual BAs on mRNA expression of BA 
transporters in ileum.  As shown in Fig S4-3, the effects of feeding five BAs on 
Asbt in ilea were not marked.  Feeding CA at concentrations of 0.3 and 1.0% in the 
diets decreased the mRNA of Asbt 31 and 41%, respectively.  Feeding CDCA and 
DCA had little effect on mRNA expression of Asbt.  In contrast, feeding of LCA at 
0.01 and 0.1% in the diets increased the mRNA of Asbt about 30%, as well as 
feeding 0.3% UDCA increased Asbt mRNA 23%.  However, UDCA at the highest 
dose (3.0% in the diet) decreased Asbt mRNA expression in ileum 26%.  
CA, only at the lowest dose (0.03% in the diet), increased the intestinal BA 
binding protein (Ibabp) mRNA 21% (Fig S4-3).  At higher doses, CA did not affect 
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the mRNA expression of Ibabp.  In contrast, only at higher doses did feeding of 
other BAs (CDCA at 0.3%, DCA at 0.1%, LCA at 0.1, and 0.3% in the diets) 
increased Ibabp mRNA 16-37%.  Feeding of UDCA at 0.1, 0.3, and 1.0% in the diets 
increased Ibabp mRNA 50-150%. 
The heterodimer transporter (Ostα/β) in ileum is essential in BA efflux from 
the enterocytes into blood (Rao et al., 2008).  As shown in Fig S4-3, mRNA of Ostα 
was regulated by feeding mice various BAs.  Ostα was increased by CA at 0.1, 0.3, 
and 1.0% in the diets about 30%, CDCA at 0.3% in the diet 31%, as well as DCA at 
0.1 and 0.3% in the diets 40-46%.  However, Ostα was not regulated by LCA at any 
concentration.  UDCA at 0.1 and 0.3% in the diets also increased Ostα mRNA 
expression in ileum 19 and 67%, respectively.  In contrast to the effect of feeding 
BAs on Ostα mRNA expression, feeding BAs had little effect on Ostβ mRNA 
expression, except that DCA at the highest concentration (0.3% in the diet) 
increased Ostβ mRNA in ileum 28%.  
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Fig 4-7  Messenger RNA expression of FXR and its target genes in ilea of mice treated with 
five BAs (CA, CDCA, DCA, LCA, or UDCA) at concentrations of 0.01, 0.03, 0.1, 0.3, 1.0, or 
3.0% in the diets.  Data are presented as Mean ± S.E.M (n=5).  *P<0.05 
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Fig S4-1  Messenger RNA expression of Ostα and β in the livers of mice treated with five 
BAs (CA, CDCA, DCA, LCA, or UDCA) at concentrations of 0.01, 0.03, 0.1, 0.3, 1.0, or 
3.0% in the diets.  Data are presented as Mean ± S.E.M (n=5).  *P<0.05 
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Fig S4-2  Messenger RNA expression of nuclear receptors and their target genes in the 
livers of mice treated with five BAs (CA, CDCA, DCA, LCA, or UDCA) at concentrations of 
0.01, 0.03, 0.1, 0.3, 1.0, or 3.0% in the diets.  Data are presented as Mean ± S.E.M (n=5).  
*P<0.05 
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Fig S4-3  Messenger RNA expression of BA transporters in the ilea of mice treated with 
five BAs (CA, CDCA, DCA, LCA, or UDCA) at concentrations of 0.01, 0.03, 0.1, 0.3, 1.0, or 
3.0% in the diets.  Data are presented as Mean ± S.E.M (n=5).  *P<0.05 
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4.4  Discussion   
It has been thought that BAs can activate their nuclear receptor FXR to 
regulate genes involved in BA biosynthesis and transport at the transcriptional level.  
To study the roles of FXR in BA regulation of genes involved in BA homeostasis,  
FXR-null mouse model, bile-duct ligation mouse model, or the potent synthetic FXR 
activator GW4064, have been used (Goodwin et al., 2000; Inagaki et al., 2005; Kim 
et al., 2007).  The data generated from the above-mentioned animal models are very 
valuable for understanding BA regulation of genes via the FXR-mediated-signaling 
pathway.  Especially in regard to the transcriptional regulation of Cyp7a1, 
conclusions have been made that it is the ileum FXR-Fgf15 signaling, but not the 
hepatic FXR-SHP signaling, that plays the major role (Inagaki et al., 2005; Kim et al., 
2007).  Given the fact that the animal models used in those studies are non-
physiological and that the FXR ligand used (GW4064) is 1000 times more potent 
than CDCA in activation of FXR (Goodwin et al., 2000), a comprehensive 
understanding of BA regulation of genes via the FXR-mediated pathway under 
normal/physiological conditions has been somewhat limited due to the lack of in vivo 
studies using intact wild-type animals fed low and non-hepatotoxic doses of 
individual BAs.  In addition, our previous study (chapter 3) shows that the total BA 
concentration in the liver remains at control levels despite remarkable variations in 
daily input of the fed-BAs (0.01%-1% in the diet).  These findings suggest that a 
wide range of adaptations probably occur in the de novo BA biosynthesis and 
transport.   
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In the present study, we demonstrate that it was hepatic FXR, but not other 
nuclear receptors (PXR, Nrf2, or CAR), that was activated by all five individual BAs 
at both low-non-hepatotoxic as well as high-hepatotoxic doses, as evidenced by 
increased mRNA expression of its major target gene SHP (Fig 4-6 and Fig S4-2).   
Herein, we characterized the adaptive changes in mRNA expression of genes 
involved in BA homeostasis that contribute to maintaining the total liver BA 
concentrations after feeding mice either low-non-hepatotoxic doses or high-
hepatotoxic doses of individual BAs, and propose possible roles of FXR in liver and 
ileum in regulating these genes.  
The data in the present study demonstrate that feeding BAs at non-
hepatotoxic doses only slightly altered BA composition in the liver without affecting 
the total BA concentration in the liver (Fig 4-1).  A surprising finding in the present 
study is that the FXR-SHP signaling pathway in the liver is activated even though 
the total BA concentration in the liver did not increase in mice fed BAs.  In fact, there 
was a similar increase in SHP mRNA in livers of mice fed low and high 
concentrations of BAs in the diets, suggesting that at relatively low concentrations 
(0.01% or 0.03% in the diets) the BA sensor FXR in liver was fully activated by 
feeding any of the five BAs.  In contrast, the FXR-Fgf15 signaling pathway in the 
ileum is activated only by feeding any dose of the 12-OH BAs (CA and DCA), but not 
by feeding low-non-hepatotoxic doses of the non-12-OH BAs (CDCA and LCA) (Fig 
4-7).  Feeding all BAs at high-hepatotoxic doses activated the ileum FXR-Fgf15 
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signaling, suggesting that the ileum FXR-Fgf15 signaling is more responsive to high 
concentrations of BAs.  
Both the hepatic FXR-SHP signaling pathway and the ileum FXR-Fgf15 
signaling pathway are involved in feedback regulation of BA biosynthesis.  The FXR-
Fgf15 signaling pathway in the ileum is proposed to play a major role in regulating 
Cyp7a1, whereas, the hepatic FXR-SHP signaling pathway is thought to play major 
roles in regulation of Cyp8b1 (Kim et al., 2007).  In agreement with previous findings, 
the present data show that Fgf15 mRNA in the ileum was dose-dependently 
increased by 12-OH BAs (CA and DCA) (Fig 4-6).  The increased Fgf15 may 
contribute to the decreased mRNA expression of Cyp7a1 in the liver by these two 
BAs.  However, the present study also shows that feeding the non-12-OH BAs 
(CDCA and LCA) at low-non-hepatotoxic doses (0.1% in the diet or lower) did not 
increase intestinal Fgf15 mRNA expression, indicating that intestinal FXR is not 
activated by these two BAs at low concentrations.  In contrast, the mRNA of the 
hepatic FXR-target gene SHP was fully induced, and the mRNA of Cyp7a1 in liver 
was decreased by all BAs, even at the lowest concentrations fed mice.  Collectively, 
the present study suggests that the hepatic FXR-SHP signaling pathway in the liver 
is more important than the intestinal FXR-Fgf15 pathway in the basal regulation of 
Cyp7a1 expression by BAs, whereas the FXR-Fgf15 signaling pathway in the ileum 
plays more important roles in mediating feedback regulation of Cyp7a1 under BA 
overloading.  This conclusion based on the present data is not fully in agreement 
with that reported in a previous study (Kim et al., 2007).  There are several plausible 
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explanations for the difference observed in the two studies: 1). The BA 
concentrations (the sum of CA, CDCA, DCA and LCA) in the BA pool of mice fed the 
CDCA or LCA at low-non-hepatotoxic doses are lower than those in mice fed CA or 
DCA at same doses.  Moreover, it was proposed that CA but not CDCA is the 
important endogenous agonist for FXR in mice (Li-Hawkins et al., 2002).  
Accordingly, it seems reasonable that the FXR-Fgf15 signaling will not be activated 
by low concentrations of CDCA or LCA.  However, considering that both CDCA and 
LCA at low doses activated hepatic FXR to a similar level as high doses,  it does not 
seem likely that low BA concentrations in mice fed CDCA or LCA is a reason for 
their not activating the FXR-Fgf15 signaling in ileum.  2). The FXR agonists used in 
the two studies are different.  In Kim’s study, the synthetic FXR activator GW4064 
was used.  GW4064 is 1000 times more potent than CDCA in activation of FXR 
(Goodwin et al., 2000).  Thus, activation of FXR in the ileum by GW4064 more likely 
represents the effects of markedly excessive BAs, but not that of the low doses of 
BAs.  The latter explanation can be supported by the data presented in Fig 5 and Fig 
6 in Kim’s report (Kim et al., 2007).  The liver-specific FXR-null mice displayed a 
decreased expression of SHP and an increased expression of Cyp7a1, suggesting 
that hepatic FXR-SHP signaling pathway is important for the basal regulation of 
Cyp7a1.  However, the ileum-specific FXR-null mice had a decreased expression of 
Fgf15, but did not display an increase in the expression of Cyp7a1 (Kim et al., 
2007), suggesting that the FXR-Fgf15 signaling pathway in the ileum is not critical in 
basal regulation of Cyp7a1 in liver.  All in all, both Kim’s data generated from the 
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liver- and ileum-specific FXR-null mice and the present data generated from feeding 
of individual BAs at low-non-hepatotoxic doses indicate that it is the hepatic FXR-
SHP signaling pathway, but not the ileum FXR-Fgf15 signaling pathway, that is 
playing central role in the basal regulation of Cyp7a1 by BAs, whereas, the ileum 
FXR-Fgf15 signaling may play a more important role when FXR is over-activated by 
overloaded BAs or potent activators such as GW4064. 
Even though the hepatic FXR-SHP signaling pathway was fully activated by 
all BAs at all doses in the present study, the putative FXR-target gene, Cyp8b1, 
unlike Cyp7a1 that is decreased by all BAs at all doses, (Wang et al., 2006; Kim et 
al., 2007; Norlin and Wikvall, 2007) was only decreased by feeding the 12-OH BAs, 
but not by the non-12-OH BAs, except at high-hepatotoxic doses.  In addition, Kim’s 
report also demonstrated that deletion of hepatic FXR increased Cyp7a1 mRNA, but 
not Cyp8b1 mRNA expression (Kim et al., 2007).  Accordingly, the data from both 
studies indicate that the hepatic FXR-SHP signaling pathway is not as critical in 
regulating Cyp8b1 as in regulating Cyp7a1.  Instead, the regulation pattern of 
Cyp8b1 in liver by various BAs is conversely correlated to the pattern of Fgf15 
expression in ileum, suggesting that the FXR-Fgf15 pathway in ileum might play an 
important role in regulating Cyp8b1.  Thus, regulation of Cyp7a1 and Cyp8b1 by 
FXR-Fgf15 may be dependent on both concentrations and species of BAs present in 
the BA pool.  
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Compared to the effects of feeding of BAs at non-hepatotoxic doses on 
mRNA expression of Cyp7a1, feeding of BAs had a less effect on the mRNA 
expression Cyp27a1 and Cyp7b1.  In mice fed non-hepatotoxic doses of BAs 
(including CA, CDCA, and DCA, but not LCA), there are slight decreases in 
Cyp27a1 mRNA expression (about 10%), and no change in Cyp7b1 mRNA 
expression, suggesting that the hepatic FXR-SHP signaling pathway may not play 
major roles in feedback regulation of the two genes.  Our conclusion is supported by 
an in vitro study which demonstrates that, the hydrophobic BAs are able to suppress 
Cyp27a1 mRNA expression without FXR presence (Chen and Chiang, 2003). 
Among all the transporters examined in the present study, only the 
cholesterol half transporter Abcg5 and g8 were increased by feeding the five BAs at 
low-non-hepatotoxic doses, other transporters, including Ntcp, Oatps, Bsep, Mrp3 or 
Mrp4, Atp8b1 and Mdr2, were not regulated by all five BAs at low-non-hepatotoxic 
doses.  In contrast, in mice fed BAs at hepatotoxic doses, there were decreases in 
the mRNA expression of Ntcp, and increases in mRNA expression of Abcg5 and g8, 
as well as Mdr2.  The alterations in mRNA expression of these transporters in mice 
fed various BAs at hepatotoxic doses may be adaptive responses to the toxic effects 
of the fed BAs. The decreased expression of Ntcp causes a decreased uptake of 
BAs, resulting in increased BA concentration in the serum (Chapter 3). In addition, 
the decreased expression of Ntcp may also contribute to maintaining the total liver 
BA concentration.   
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The increased mRNA expression of Abcg5 and g8 after feeding various 
doses of BAs could be due to an indirect effect of BAs.  Feeding mice BAs at even 
the lowest doses fully inhibited the mRNA expression of Cyp7a1 (Fig 4-1); thus 
feeding mice BAs is likely to result in an accumulation of cholesterol and oxysterols 
(Murphy et al., 2005), which are known activators of LXR.  The activation of LXR by 
oxysterols leads to up-regulation of Abcg5/g8 (Repa et al., 2002).  Increased 
expression of Abcg5/g8 leads to an increase in the biliary secretion of cholesterol 
(Yu et al., 2002).  The increased expression of Mdr2 mRNA after feeding the BAs at 
high-hepatotoxic doses could be an adaptive response to BA toxicity.  The 
corresponding increase in Mdr2 may contribute to increased secretion of 
phospholipids into bile (Smit et al., 1993; Kneuer et al., 2007; Funk, 2008).  Our 
previous study (Chapter 3) showed that feeding individual BAs at hepatotoxic doses 
altered liver BA composition and caused hepatotoxicity.  The increased secretion of 
phospholipid together with increased secretion of cholesterol to form more mixed 
micelles with BAs may contribute to limiting the hepatotoxicity of BAs. 
In summary, in mice fed low-non-hepatotoxic doses of individual BAs, the 
total liver BA concentrations were maintained via hepatic FXR-SHP mediated 
suppression of Cyp7a1, whereas the liver BA composition was somewhat restored 
via ileum FXR-Fgf15 mediated regulation of Cyp8b1 in a BA-species-dependent way.  
Whereas, in mice fed hepatotoxic doses of individual BAs, both Cyp7a1 and Cyp8b1 
were suppressed by all BA species via activation of both the hepatic FXR-SHP and 
ileum FXR-Fgf15 signaling pathways, resulting in unchanged total liver BA 
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concentration and an imbalanced liver BA composition, which appears to contribute 
to the hepatotoxicity of BAs.  In addition, decreases in the major BA uptake 
transporter Ntcp in the livers of mice fed high-hepatotoxic doses of individual BAs 
may also contribute to maintaining the total liver BA concentration, whereas, the 
increases in the lipid transporters Abcg5/g8 and Mdr2 may indicate an increased 
secretion of cholesterol and phospholipids, which form micelles with BAs and 
contribute to limiting the hepatotoxicity of BAs.  
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CHAPTER 5 
EFFECTS OF CHOLESTYRAMINE ON LIVER BILE ACID COMPOSITION AND 
EXPRESSION OF GENES INVOLVED IN BILE ACID HOMEOSTASIS IN MICE 
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5.1  Abstract 
The hypocholesterolemic drug cholestyramine (resin) functions by 
sequestration of BAs in the intestine.  Administration of the resin increases the 
mRNA expression and enzyme activity of Cyp7a1, a key enzyme in the BA-
biosynthesis pathway, resulting in increased conversion of cholesterol into BAs.  
However, the effects of resin on the liver BA concentration and composition and the 
subsequent alteration in BA receptor mediated signaling pathway is unknown.  
Therefore, mice were fed 2% resin in their diets for one week.  The BAs in both the 
serum and the liver, as well as the mRNA involved in BA homeostasis were 
quantified.  The data demonstrated that the resin tended to increase the serum total 
BA concentration, and significantly decreased β-MCA concentration 50%, but 
increased CA and T-CA in sera.  As expected, feeding mice the resin decreased the 
total liver BA concentration 80%, which was due to an  almost complete depletion of 
α-, β-, and ω-MCAs, as well as their taurine conjugates, and less of a decrease in 
most of the other BAs.  In addition, the resin also altered the BA composition in the 
liver, featured by an increase in the percentage of the total CA and the secondary 
BA DCA.  The mRNA of the BA-biosynthesis enzymes, Cyp7a1 and Cyp8b1, 
increased 180 and 100% respectively.  However, the FXR-target gene SHP in liver 
was not decreased.  In contrast, the ileum Fgf15 mRNA expression was significantly 
decreased.  Feeding the resin did not alter the BA uptake transporters on the 
sinusoidal membrane nor did it altered the efflux transporters on the canalicular 
membrane, whereas, the efflux transporters on the sinusoidal membrane of 
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hepatocytes, Mrp 3 and 4, were increased by the resin 22 and 150% respectively.  
In ileum, feeding the resin increased the uptake transporter, Asbt, 66%.  Collectively, 
the data suggest that increased expression of Cyp7a1 and Cyp8b1 in mouse liver by 
resin administered through the diet appears to be due to a decrease in the ileum 
Fgf15 signaling pathway, rather than a decrease in hepatic FXR signaling pathway.  
5.2  Introduction 
BAs are biosynthesized from the precursor cholesterol in liver, and the 
biosynthesis of BAs is a major pathway for the elimination of cholesterol from the 
body.  BA biosynthesis is negatively regulated by BAs themselves via multiple 
signaling pathways.  Since the discovery of the BA nuclear receptor FXR, the critical 
roles of the FXR mediated signaling pathways in regulation of major BA biosynthesis 
enzymes has been determined.  FXR-mediated suppression of Cyp7a1 in mice is 
thought to be the predominant mechanism for the regulation of BA biosynthesis and 
is able to override LXR-mediated up-regulation of Cyp7a1 (Wang et al., 2006).  In 
addition, the hepatic FXR-SHP mediated signaling pathway is proposed to play a 
major role in the regulation of Cyp8b1, which determines the ratio between CA (a 
12-OH BA) and CDCA (a non-12-OH BA) in the BA pool, whereas, the intestinal 
FXR-Fgf15 mediated signaling pathway mainly plays a role in suppression of 
Cyp7a1 (Goodwin et al., 2000; Inagaki et al., 2005).  However, our previous study 
showed that feeding the two 12-OH BAs (CA and DCA) activated not only the 
hepatic FXR-SHP signaling pathway, but also the ileum FXR-Fgf15 signaling 
pathway and caused a maximum suppression of the mRNA expression of Cyp7a1, 
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suggesting the suppression of Cyp7a1 by the two 12-OH BAs is mediated by both 
the hepatic FXR-SHP and the ileum FXR-Fgf15 signaling pathways.  In contrast, 
feeding the two non-12-OH BAs (CDCA and LCA) at non-hepatotoxic doses only 
activated the hepatic FXR-SHP signaling, but not the ileum FXR-Fgf15 signaling 
pathway, resulting in a less suppression of the mRNA expression of Cyp7a1 
compared to the suppression level in mice fed the 12-OH BAs at non-hepatotoxic 
doses.  Only at high and hepatotoxic doses, did the two non-12-OH BAs activate 
both the hepatic FXR-SHP and the ileum FXR-Fgf15 signaling, resulting in 
maximum suppression of Cyp7a1. Our data suggest that the hepatic FXR-SHP 
signaling pathway plays major role in the basic regulation of Cyp7a1 or low doses of 
BAs  (unpublished data).   
BA composition in the enterohepatic circulation plays important roles in 
regulating BA biosynthesis and transport, the excretion of lipids into bile, as well as 
intestinal absorption of cholesterol (Heuman et al., 1989; Pandak et al., 2001).  
Feeding mice CA stimulates the excretion of cholesterol and phospholipids into bile, 
whereas other major BAs in mice, namely MCAs (α- and β-MCA), do not increase 
the hepatic excretion of lipids (Kubitz et al., 2005; Wagner and Trauner, 2005).  BAs 
also vary in their ability to regulate BA biosynthesis and hepatobiliary transport.  For 
example, the four major human BAs fed to mice at various concentrations in their 
diets differ markedly in their ability to regulate Cyp8b1 mRNA expression.  Cyp8b1 is 
a 12α-hydroxylase that produces CA.  Without the presence of Cyp8b1, CDCA is the 
final product (Vlahcevic et al., 2000).  Thus Cyp8b1 determines the ratio between 
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12-OH BA (CA) and non-12-OH BA (CDCA) in liver (Pandak et al., 2001).  Feeding 
the 12-OH-BAs (CA or DCA) decreased Cyp8b1 expression, whereas at the same 
concentrations in the diets, feeding the non-12-OH BAs (CDCA or LCA) had no 
effect on Cyp8b1 mRNA expression (Chapter 4).  Moreover, Cyp8b1-null mice, 
which lack CA, have decreased expression of the FXR-target gene, SHP suggesting 
that CA is a major activator of FXR in mice (Murphy et al., 2005).  
Cholestyramine (resin), a non-absorbable ionic exchange resin, is a 
cholesterol-lowering drug that binds BAs in the intestine and increases their fecal 
excretion (Thompson, 1971).  The decreased enterohepatic circulation of BAs 
results in increased catabolism of cholesterol into BAs.  The ultimate mechanism for 
decreasing cholesterol after resin treatment is the increase in mRNA expression and 
enzyme activity of Cyp7a1, which is the rate-limiting enzyme in BA biosynthesis 
(Thompson, 1971; Nilsson et al., 2007).  Although the resin is a non-absorbable 
drug, it has been found to regulate glucose homeostasis and to improve 
atherosclerotic coronary heart disease, which are thought to have little to do with its 
lipid lowering effects (Bays and Goldberg, 2007).  The binding efficiency of various 
BAs to resin varies (Thompson, 1971).  The relatively hydrophobic BAs (DCA and 
LCA) bind more strongly to the resin than do the hydrophilic BAs (CA and MCA) at 
the pH of the intestine (about 6.0) (Whiteside et al., 1966; Thompson, 1971; Story 
and Kritchevsky, 1976).  Thus, feeding mice resin is likely to not only decrease 
absolute BA concentrations in liver, but also alter BA composition, as well as 
expression of genes involved in BA biosynthesis and transport.  Therefore, the 
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purpose of this study was to determine the effects of resin on BA concentrations and 
BA composition in the livers of mice, as well as the subsequent alteration in the 
expression of genes encoding BA biosynthesis enzymes, transporters, and 
transcription factors in both liver and ileum.  
5.3  Results 
Total BA Concentrations in Serum and Liver.  As shown in Fig 5-1, 
feeding mice 2% resin in the diet tended to increase the total BA concentration in 
serum and significantly decreased total BA concentration in liver 80%. 
 
Fig 5-1. Total BA concentrations in sera and livers of mice fed a control diet and a 2% resin-
supplemented diet for one week.  Data are presented as Mean ± S.E.M (n=5).  *P<0.05. 
 
Individual BA Concentrations in Serum.  As shown in Fig 5-2, feeding mice 
the resin-supplemented diet surprisingly increased T-CA as well as the total CA (CA 
plus T-CA).  In contrast, feeding mice the resin supplemented diet trended to 
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increase the concentrations of other BAs (DCA, LCA, UDCA, and their taurine 
conjugates), but significantly decreased β-MCA in sera.  
 
 
Fig 5-2.  BA concentrations in sera of mice fed a control diet and a 2% resin-supplemented 
diet for one week.  Data are presented as Mean ± S.E.M (n=5).  *P<0.05. 
 
Individual BA Concentrations in Liver.  As shown in Fig 5-3, feeding mice 
2% resin decreased the concentrations of various BAs in liver.  For example, CA, T-
CA, and total CA decreased 70-80%, and CDCA decreased 37% by feeding the 
resin, whereas T-CDCA and total CDCA were not significantly altered by feeding the 
resin.  DCA, T-DCA, and total DCA decreased 35-60%, and LCA, T-LCA, total LCA, 
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UDCA, T-UDCA, and total UDCA all decreased about 85%.  In addition, feeding 
mice the resin decreased MCAs and T-MCAs (α-, β-, and ω-MCA) 80-99%. Feeding 
mice the resin also decreased HDCA, MDCA and their taurine conjugates 65-94%.  
BA composition in Liver.  Feeding mice the resin-containing diet not only 
decreased total BA concentrations in liver, but also altered the percentage of each 
BA relative to total BAs in liver.  As shown in Fig 5-4, the percentage of the total CA 
(CA+T-CA) in the livers of mice fed the resin increased from 39.4 to 63.8%, whereas, 
the percentage of the total MCA (MCAs+T-MCAs) decreased from 52.7 to 14.4%.  
The percentage of the total CDCA (CDCA+T-CDCA), that of the total DCA (DCA+T-
DCA), and that of the total LCA (LCA+T-LCA) in the livers of mice fed the resin also 
increased from 1.5 to 7.6%, 2.7 to 9.8%, and 0.2 to 1.0% respectively.  The 
percentage of other BAs relative to the total BA concentration in the livers of mice 
fed the resin, including the total UDCA and the total 6-OH BAs (HDCA and MDCA 
plus their taurine conjugates), did not change.  
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Fig 5-3.  BA concentrations in livers of mice fed a control diet and a 2% resin-supplemented 
diet for one week.  Data are presented as Mean ± S.E.M (n=5).  *P<0.05. 
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Fig 5-4.  Liver BA composition (% of total BAs) in mice fed a control diet and a 2% resin 
supplemented diet for one week. 
 
Effect of feeding the resin-containing diet on messenger RNA 
expression of BA-biosynthesis enzymes in liver.  As shown in 5-5A, after feeding 
the resin-containing diet for one week, Cyp7a1 mRNA expression was increased 
about 180%.  Feeding the resin-supplemented diet increased Cyp8b1 about 100%.   
Feeding mice the resin-containing diet had no effect on Cyp27a1 mRNA 
expression (Fig 5-5A).  Whereas the resin-containing diet almost tripled Cyp7a1 
mRNA expression, it did not alter Cyp7b1 mRNA expression.   
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Effect of feeding the resin-containing diet on messenger RNA 
expression of uptake transporters in liver.  As shown in Fig 5-5B, after feeding 
the resin-containing diet for one week, Ntcp mRNA expression was not altered. 
Members of the organic anion transporter family (Oatp/Slco) function as 
uptake transporters for a wide variety of xenobiotics and endogenous chemicals, 
including BAs.   In addition to Ntcp, Oatp1a1, 1a4, and 1b2 are also thought to be 
involved in BA uptake into liver (Jacquemin et al., 1994; Kullak-Ublick et al., 1994; 
Meier and Stieger, 2002; Hagenbuch and Meier, 2003).  As shown in Fig 5-5B, 
feeding mice the resin-containing diet increased Oatp1a4 mRNA about 70%, but it 
did not alter Oatp1a1 or 1b2 mRNA expression. 
Effect of feeding the resin-containing diet on messenger RNA 
expression of efflux transporters in liver.  The effect of feeding the resin-
supplemented diet on hepatic efflux transporter mRNA expression is shown in Fig 5-
5C.  After feeding the resin-containing diet for one week, the mRNA of the BA-efflux 
transporter Bsep was decreased about 18.6%.   
In addition to the efflux of BAs by Bsep into canaliculi, Mrps are involved in 
BA efflux from hepatocytes to either bile (Mrp2) or blood (Mrp3 and 4) (Keppler and 
Konig, 1997; Meier and Stieger, 2002).  The resin-containing diet had no effect on 
Mrp2 mRNA expression, but increased the mRNA expression of Mrp3 and 4 (22% 
and 150%, respectively) (Fig 5-5C).  Ostα and β are localized on the sinusoidal 
membranes of hepatocytes, mediating the efflux of BAs back into blood.  As shown 
in Fig 5-5C, after feeding the resin, Ostα/β mRNA was not significantly altered. 
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Effect of feeding the resin-containing diet on the messenger RNA 
expression of Abcg5 and Abcg8 in liver.  Abcg5 and g8 are half-transporters for 
cholesterol elimination from hepatocytes into bile.  The effect of the resin-containing 
diet on Abcg5 and g8 mRNA expression is shown in Fig 5-5D.  After feeding the 
resin-containing diet for one week, the mRNA of Abcg5 and g8 did not change.   
 
Fig 5-5.  Messenger RNA expression of genes involved in BA biosynthesis (A), BA uptake 
(B), BA efflux (C), as well as cholesterol efflux transporters Abcg5 and Abcg8 (D) in livers of 
mice fed a 2% resin-supplemented diet for one week.  Data are presented as Mean ± S.E.M 
(n=5).  *P<0.05.  
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Effect of feeding the resin-containing diet on the messenger RNA 
expression of nuclear receptors and their target genes in liver.  As shown in Fig 
5-6, feeding mice the resin-containing diet does not appear to affect the mRNA 
expression of the nuclear receptor FXR, or its activation, because its target gene 
SHP did not increase in liver.  Fig 5-6 also shows that feeding the resin-containing 
diet had no effect on the expression of PXR mRNA expression, but it decreased the 
expression of the PXR-target gene Cyp3a11 about 10%.  The resin-containing diet 
did not increase mRNA of Nrf2, but increased the expression of its target gene Nqo1 
80%, indicating that feeding the resin-containing diet activated Nrf2.    
 
 
Fig 5-6.   Messenger RNA expression of nuclear receptors and their target genes in livers of 
mice fed a 2% resin-supplemented diet for one week.  Data are presented as Mean ± S.E.M 
(n=5).  *P<0.05.  
 
117 
Effect of feeding the resin-containing diet on the messenger RNA 
expression of BA transporters in ileum.  The effects of the resin-containing diet 
on BA transporters in the ileum are shown in Fig 5-7.  In the ileum, the BA uptake 
transporter Asbt is localized on the apical membrane of enterocytes (Kramer et al., 
1982; Wong et al., 1994; Shneider et al., 1995).  Asbt is responsible for the uptake 
of BAs from the intestinal lumen into enterocytes.  After feeding the resin-containing 
diet for one week, Asbt mRNA expression was increased 66%. 
The cytosolic intestinal BA-binding protein (Ibabp) is responsible for the 
intracellular transport of BAs from the apical side to the basolateral side of 
enterocytes (Meier and Stieger, 2002).  After feeding mice the resin-containing diet 
for one week, the Ibabp mRNA expression did not change (Fig 5-7).  
The organic solute transporter (Ostα/Ostβ) is the main BA transporter that 
effluxes BAs from enterocytes into blood.  The resin did not alter Ostα/Ostβ mRNA 
expression (Fig 5-7).  In addition to Ostα/Ostβ, the multiple drug resistant protein 
Mrp3 is located on the basal membrane of enterocytes and might have a role in BA 
efflux from inside the enterocytes to the portal blood.  As shown in Fig 5-7, the resin-
containing diet did not alter the mRNA expression of Mrp3.  
Effect of feeding the resin-containing diet on the messenger RNA 
expression of nuclear receptors and their target genes in ileum.  As shown in 
Fig 5.8, FXR mRNA in the ileum was not altered by feeding the resin-containing diet.  
Although feeding mice the resin-containing diet did not alter the FXR-target gene 
SHP, it markedly decreased the FXR-target gene Fgf15 in the ileum.  
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Fig 5-7. Messenger RNA expression of BA transporters in ileum of mice treated with 2% 
Resin in the diets for one week.  Data are presented as Mean ± S.E.M (n=5).  *P<0.05. 
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Fig 5-8.  Messenger RNA expression of nuclear receptors and their target genes in ileum of 
mice fed a 2% resin-supplemented diet for one week.  Data are presented as Mean ± S.E.M 
(n=5).  *P<0.05. 
 
5.4  Discussion  
The present study characterizes the pharmacological effects of the resin (2% 
in the diet) on BA concentrations in sera and liver, as well as the expression of 
genes involved in BA homeostasis.  The present data indicate that the resin-
containing diet not only decreased the total liver BA concentration as expected, but 
also altered the liver BA composition.  The alterations in BA concentration and 
composition in the enterohepatic circulation after feeding mice the resin-containing 
diet resulted in a diminished ileum FXR-Fgf15 signaling, but it did not affect the 
hepatic FXR-SHP signaling.  
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An unexpected finding in this study was that the serum total BA concentration 
tended to increase and the T-CA in serum increased significantly.  It has been 
noticed for decades that the cholestyramine resin is able to improve the glucose 
homeostasis in diabetes patients and various potential mechanisms for glucose-
lowering effects of resin have been proposed (Staels, 2009).  In this study, we report 
that the serum BA composition is altered after resin-feeding.  The total CA 
concentration was increased whereas the βMCA concentration decreased.  
Accordingly, we propose an original hypothesis in regarding to the glucose lowering 
effects by cholestyramine: The increased CA in the systemic circulation may cause 
activation of the TGR5 receptor in the skeletal muscles and the lipid tissues, 
resulting in increased glucose metabolism.    
Even though the total liver BA concentration decreased 80% after feeding 
mice the 2% resin-containing diet, the percentage of the total CA (CA+T-CA) relative 
to the total BAs in the liver was increased from 39.4 to 63.8%.  The concentration of 
the total CA in the livers of the resin-fed mice (30 nmol/g) is 29.1% of that of the 
control mice (106 nmol/g) (Fig 5-4).  The increase in the percentage of the total CA 
after the 2% resin-containing diet is at least partially due to the increased expression 
of Cyp8b1 (Fig 5-5) and thus the de novo biosynthesis of CA.   
BAs are known activators of FXR (Grober et al., 1999; Makishima et al., 
1999).  BAs not only activate the FXR-SHP pathway in liver, but also activate the 
FXR-Fgf15 signaling pathway in the ileum of mice (Inagaki et al., 2005).  The 
fibroblast growth factor 15 (Fgf15) in mouse intestine has been shown to be induced 
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by CA feeding (Inagaki et al., 2005), and Fgf15 is thought to travel via the portal vein 
to the liver where it activates the cell surface fibroblast growth factor receptor 
(FGFR4), causing repression of hepatic Cyp7a1.  Both the FXR-SHP signaling 
pathway in liver (Goodwin et al., 2000) and the FXR-Fgf15 signaling pathway in 
ileum are involved in inhibition of Cyp7a1 expression (Inagaki et al., 2005; Kim et al., 
2007). 
It might be expected that the decreased concentration of BAs in mouse liver 
after feeding the resin-containing diet would result in diminished activation of FXR 
and thus reduced expression of SHP in liver, resulting in an increase in Cyp7a1 (Fig 
5-5).  Consistent with previous reports (Thompson, 1971; Nilsson et al., 2007), 
feeding mice the resin-containing diet increased the rate-limiting BA-biosynthesis 
enzyme in the classic pathway, Cyp7a1.  However, the present data demonstrate 
that neither SHP nor FXR mRNA expression in liver is altered by feeding mice the 
resin-containing diet (Fig 5-6).  In marked contrast, Fgf15 mRNA was decreased 
about 90% by feeding mice the resin (Fig 5-.8).  In addition, consistent with previous 
reports (Repa et al., 2002; Shibata et al., 2007), the positive regulator of Cyp7a1, 
the liver X receptor (LXR), was not activated after the resin-containing diet, indicated 
by unchanged expression of its target gene Abcg5/g8 (Fig 5-5D).  Thus, the 
increased expression of Cyp7a1 in mice fed the resin-containing diet is more likely 
due to decreased expression of Fgf15 in ileum, rather than altered FXR-SHP 
signaling and/or activation of LXR in liver. 
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The resin containing diet also induced the mRNA of Cyp8b1, an enzyme 
necessary for the biosynthesis of CA, but did not increase the mRNA of enzymes in 
the alternative pathway, such as Cyp27a1 or Cyp7b1.  The increased expression of 
Cyp8b1 is likely the reason for the increased percentage of CA relative to total BAs 
in liver after feeding the resin-containing diet (Fig 5-5).  Our previous BA-feeding 
study showed that feeding mice non-hepatotoxic doses of CA (0.03% in the diet) or 
its secondary BA, DCA, activated FXR-Fgf15 signaling in ileum and reduced Cyp8b1 
in liver (Chapter 4).  Consistent with this previous study, the current studies suggest 
that the FXR-Fgf15 signaling pathway from the intestine appears to play an 
especially important role in regulating Cyp8b1 in liver. 
The present data also demonstrate that feeding the resin-containing diet 
results in a small decrease (10%) in the putative PXR-target gene Cyp3a11 and an 
increase (80%) in the Nrf2-target gene Nqo1 (Fig 5-6 ).  The effects of feeding the 
resin-containing diet on the expression of these two genes (Cyp3a11 and Nqo1) are 
similar to those observed after feeding of BAs at hepatotoxic doses (Chapter 4).  
Although the two studies may appear contradictory in that one increased BA 
concentrations in liver, whereas the other decreased BA concentrations in liver, both 
studies resulted in increased percentages of the secondary BA, DCA (from 2.7 to 
9.8%), which is known to activate Nrf2 (Tan et al., 2007).  Thus the increased 
secondary BA concentrations in liver after either BA- or resin-feeding are likely the 
reason for Nrf2 activation. 
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The present study indicates that feeding the resin-containing diet did not alter 
the expression of uptake transporters, Ntcp, Oatp1a1, and Oatp1b2 in mouse livers.  
It has been hypothesized that high concentrations of BAs in liver activates FXR, 
which then induces the production of the repressor SHP, causing a decrease in the 
mRNA expression of the BA uptake transporter Ntcp (Gartung et al., 1996; Sauer et 
al., 2000).  However, an in vitro study indicates that inhibition of the Ntcp promoter 
activity by SHP is species-dependent; that is, SHP inhibits rat Ntcp, but not mouse 
or human Ntcp (Jung et al., 2004).  Our previous study also demonstrated that 
feeding mice low-non-hepatotoxic doses of BAs did not affect the mRNA expression 
of Ntcp, Oatp1a1, and 1b2 (Chapter 4).  Thus, BAs do not appear to be involved in 
basal regulation of these BA transporter genes via the hepatic FXR-mediated 
pathway. 
Similar to the effects of feeding BAs on Oatp1a4 expression (Chapter 4), 
feeding mice the resin-containing diet also increased Oatp1a4 mRNA expression.  
Oatp1a4 expression is regulated by Nrf2 (Cheng et al., 2005).  As mentioned 
previously, Nrf2 was activated by feeding both the resin-containing diet and BA-
supplemented diets.  Thus, both the BA-feeding study and the present resin-feeding 
study suggest that the increased Oatp1a4 may be due to Nrf2 activation. 
Bsep and Mrp2 are located on the canalicular membrane of hepatocytes and 
mediate the efflux of BAs into bile canaliculi.  BAs are thought to regulate Bsep 
expression primarily via their nuclear receptor FXR (Ananthanarayanan et al., 2001; 
Plass et al., 2002).  The present data show that feeding mice the resin-containing 
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diet resulted in a small decrease (10%) in the expression of Bsep, but had no effect 
on the mRNA expression of Mrp2.  Our previous study with feeding non-hepatotoxic 
doses of BAs to mice also indicates that BAs do not have major effects on Bsep 
regulation (Chapter 4).  In addition, feeding the resin-containing diet did not affect 
Mrp2 mRNA, another BA efflux transporter on the canalicular membrane of 
hepatocytes.   
An unexpected finding in the present study is that hepatic Mrp3 and Mrp4 
mRNA was increased after resin feeding.  Increased Mrp3 and Mrp4 expression 
during cholestasis is considered to be a compensatory mechanism for the removal 
of toxic BAs from hepatocytes (Slitt et al., 2007).  Thus, the increased expression of 
Mrp3 and 4 in the present study may also contribute to increased BA concentrations 
in serum (Fig 5-2).  Activation of Nrf2 is known to induce Mrp3 and Mrp4 in mice 
(Maher et al., 2008).  Both the resin-feeding study and the BA-feeding study showed 
that the Nrf2 receptor was activated.  Thus, the increases in Mrp3 and 4 mRNA 
expressions after feeding the resin-containing diet might be due to Nrf2 activation.  
The organic solute transporter (a heterodimer of Ostα and β) is located on the 
basolateral membrane of both hepatocytes and cholangiocytes (Ballatori et al., 
2005).  Both Ostα and β are thought to be regulated by FXR (Boyer et al., 2006).  
The present data demonstrate that the resin did not affect Ostα and β mRNA 
expression in liver.  This might be because the hepatic FXR was not activated after 
feeding mice the resin-containing diet. 
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Feeding the resin-containing diet almost completely abolished the expression 
of the ileum FXR target gene Fgf15 mRNA (Fig 5-8).  The decrease in Fgf15 mRNA 
may be due to a reduction of the major FXR agonist in mice fed resin-containing diet, 
namely CA.  However, the decreased activation of FXR after feeding the resin-
containing diet did not affect the mRNA expression of other FXR target genes SHP, 
Ostα/β and Ibabp (Grober et al., 1999; Goodwin et al., 2000; Lu et al., 2000) .  
Surprisingly, the mRNA of Asbt in ileum, another FXR target gene, was increased 
66% after feeding mice the resin-containing diet (Fig 5-7), suggesting that a FXR-
independent signaling pathway may exist in regulating the Asbt. 
In summary, feeding mice the resin-containing diet decreased the total BA 
concentrations in liver 80% and altered BA composition in liver.  The ileum FXR-
Fgf15 signaling pathway was inhibited 97%, whereas, the hepatic FXR-SHP 
signaling pathway was not affected by feeding the resin-containing diet.  The 
diminished FXR-Fgf15 signaling in the ileum is likely responsible for the increased 
mRNA expression of Cyp7a1 and Cyp8b1.  In addition, the mRNA expression of the 
sinusoidal BA efflux transporters Mrp3 and Mrp4 were increased by feeding the 
resin-containing diet, which may be due to activation of Nrf2, a known regulator of 
Mrp transporters.  However, no marked alterations in either the BA uptake 
transporter Ntcp or the efflux transporter, Bsep, were observed in mice fed the resin-
containing diet. 
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CHAPTER 6 
SUMMARY AND CONCLUSION 
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6.1 Altered BA Composition in Liver Contributes to the Hepatotoxicity of 
Individual BAs. 
The major function of BAs was thought to facilitate lipid absorption in the 
intestine for a long time after the Nobel Prize laureate Heinrich Wieland determined 
the molecular structures of BAs in 1927 (Witkop, 1992).  The discovery of FXR in 
1999 as a BA receptor ushered in a new era of BA research (Parks et al., 1999; 
Wang et al., 1999).  BAs are now recognized as endocrine molecules that regulate 
the homeostasis of BAs, cholesterol, glucose, and energy.  Given all these important 
physiological functions of BAs, BAs and their receptors as potential pharmaceutical 
targets for the treatment of various metabolic diseases have been proposed 
(Lefebvre et al., 2009; Zollner and Trauner, 2009). 
However, in the long history of BA research, a simple but fundamental 
question has been overlooked, that is, what is the proper dose for each individual 
BA to study their physiological functions or toxicity in vivo?  This question was 
addressed in the first study (Chapter three) of my dissertation, using a strictly 
designed experimental system.  The data showed: 1) LCA, DCA, and CDCA at 1.0% 
in the diets were lethal, whereas CA at 1% and UDCA at 3.0% were not lethal.  2) 
Using both serum ALT activity and BA concentration as indices of liver function, the 
doses of each BA that produce hepatotoxicity are as follows: LCA 0.03% or above, 
DCA at 0.1% or above, and CDCA and CA at 0.3% in the diet or above, whereas, 
UDCA at 0.3% in the diet or above might be hepatotoxic because it only caused 
increases in serum BA concentration, but not serum ALT.  3) Feeding BAs (CA, 
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CDCA, DCA, or LCA) at hepatotoxic doses did not alter the total liver BA 
concentration; however it altered the liver BA composition, featured by increases in 
the percentage of the fed-BAs, and decreases in the percentage of MCAs. 
In conclusion, the imbalance in the BA composition in liver after feeding mice 
hepatotoxic doses of BAs appears to contribute to their hepatotoxicity.  Furthermore, 
to study the physiological or pharmacological functions of each BA, non-hepatotoxic 
doses of BA should be used, namely, CA and CDCA at 0.1% or lower, DCA at 
0.03% or lower, and LCA at 0.01% in the diet.  Given the fact that high doses of 
UDCA produced increased serum BA concentration, UDCA at 0.1% or lower in the 
diets are recommended to use for the study of its pharmacological functions. 
6.2   Adaptive Gene Expression in Response to Altered Liver BA Composition 
in Mice Fed Non-hepatotoxic Doses or Hepatotoxic Doses of BAs 
FXR plays important roles in the regulation of BA biosynthesis and transport.  
It has been established that both the hepatic FXR and the ileum FXR are involved in 
regulation of the BA biosynthesis enzyme Cyp7a1 (Goodwin et al., 2000; Inagaki et 
al., 2005).  In 2007, it was reported that the hepatic FXR-SHP signaling pathway 
plays a more important role in regulation of Cyp8b1, which determines the ratio 
between CA and CDCA, whereas, the ileum FXR-Fgf15 signaling pathway plays a 
major roles in the regulation of Cyp7a1 (Kim et al., 2007).  The first study in this 
dissertation determined the low-non-hepatotoxic doses and high-hepatotoxic doses 
of each BA.  The data obtained from the first study (chapter three) also showed that 
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feeding mice BAs at either low-non-hepatotoxic or high hepatotoxic doses did not 
increase the total liver concentration of BAs, suggesting possible adaptive 
responses in the expression of genes involved in BA biosynthesis and transport.  
Thus, the purpose of the study described in chapter four of this dissertation was to 
investigate the adaptive responses in the expression of genes involved in BA 
homeostasis, and the possible roles of the hepatic and the ileum FXR signaling 
pathways in regulating these genes in mice fed low-non-hepatotoxic doses and high-
hepatotoxic doses of BAs. 
The data indicate that only the target gene of FXR, SHP, was induced by all 
five BAs at both low-non-hepatotoxic and high-hepatotoxic doses, but not the target 
genes of other nuclear receptors, suggesting that the five BAs specifically activated 
FXR.  Corresponding to the increased SHP mRNA in liver, the Cyp7a1 mRNA, but 
not the Cyp8b1 mRNA in liver, was decreased in mice fed all doses of BAs, 
suggesting that the FXR-SHP signaling pathway was involved in suppression of 
Cyp7a1, but not Cyp8b1.  In contrast, the ileum FXR-target gene Fgf15 was induced 
by CA and DCA at low-non-hepatotoxic doses, but not by these doses of CDCA or 
LCA, suggesting that activation of FXR in the ileum is BA species dependent.  
Corresponding to the BA species specific activation of the ileum FXR-Fgf15 
signaling, the hepatic Cyp8b1 mRNA was inhibited only by CA and DCA, but not 
CDCA or LCA at non-hepatotoxic doses, indicating that the ileum FXR-Fgf15 mRNA 
plays major role in suppression of Cyp8b1.  In contrast to the effects of the five BAs 
on the BA biosynthesis enzymes, low-non-hepatotoxic doses of the five BAs did not 
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have obvious effects on mRNA expression of the BA transporters, but high-
hepatotoxic doses of the five BAs decreased the mRNA expression of the major BA 
uptake transporter Ntcp.  Interestingly, the cholesterol transporter Abcg5/g8 was 
induced by all five BAs at both low-non-hepatotoxic and high-hepatotoxic doses,  
whereas, the mRNA of the phospholipid transporter Mdr2 was induced by all five 
BAs only at high-hepatotoxic doses. 
 In conclusion, feeding the five BAs at non-hepatotoxic doses and hepatotoxic 
doses triggers different, but partially overlapping, adaptations in the gene expression 
involved in BA and lipid homeostasis.  At low-non-hepatotoxic doses, all BA species 
inhibited Cyp7a1 mRNA expression, apparently via activation of the hepatic FXR-
SHP signaling pathway, resulting in reduced de novo biosynthesis of BAs.  The BA-
species specific inhibition of Cyp8b1 by CA and DCA, is likely mediated by activating 
the ileum FXR-Fgf15 signaling pathway.  The decreased expression of Cyp8b1 
results in decreased biosynthesis of CA and DCA, but not CDCA and LCA, 
accordingly, the balance of BA composition in liver is maintained and probably aids 
in preventing hepatotoxicity of the fed-BAs.  At high-hepatotoxic doses, all BAs 
inhibited both BA biosynthesis enzymes (Cyp7a1 and Cyp8b1) and the major BA-
uptake transporter, Ntcp, which probably contributes to maintaining the total liver BA 
concentration.  The increased expression of lipid transporters Abcg5/g8 and Mdr2 
may result in increased secretion of lipids into bile, which may contribute to 
reduction of the hepatobilliary damage by BAs. 
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6.3  BA Sequestration by Resin-feeding increased the mRNA expression 
Cyp7a1 and Cyp8b1 due to diminished ileum FXR-Fgf15 signaling, but not 
reduced hepatic FXR-SHP signaling 
An increased mRNA expression of Cyp7a1 was found after resin 
administration.  Even though the mechanism for up-regulation of Cyp7a1 mRNA 
expression by resin has been investigated or proposed, such as the roles of nuclear 
receptors in liver (FXR, LXR, HNF4α), no conclusive mechanism has been found 
(Shibata et al., 2007).  Our previous BA-feeding study demonstrated that the primary 
murine BA, CA, at very low-non-hepatotoxic dose (0.03% in the diet) suppressed 
Cyp7a1 mRNA expression, probably via activation of both hepatic FXR-SHP 
signaling pathway and the ileum FXR-Fgf15 signaling pathway (Chapter 4).  The 
resin removes BAs from the normal enterohepatic circulation by sequestration of 
BAs in the intestine.  Thus, the increased mRNA expression of Cyp7a1 by resin-
feeding is likely because the loss of BAs diminished the suppressive effect of ileum 
FXR-Fgf15 signaling, which is activated by CA under normal condition. 
Mice were fed 2% resin in their diets for one week.  The BAs in both the 
serum and the liver, as well as the mRNA involved in BA homeostasis were 
quantified.  As expected, feeding mice the resin decreased the total liver BA 
concentration 80%, however, contrary to expectation, resin-feeding did not decrease 
the total serum BA concentration, but rather it increased the CA and T-CA 
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concentrations in sera.  Only the β-MCA in sera was decreased, but not the other 
BAs. Increased serum total CA concentration may be responsible for the serum 
glucose-lowering effect that the resin was found to have in type 2 diabetes patient 
(Staels, 2009).  In addition, the resin also altered the liver BA composition, in which 
there is an increase in the percentage of the total CA and that of the secondary BA 
DCA.  The mRNA of the BA-biosynthesis enzymes, Cyp7a1 and Cyp8b1, was 
increased 180 and 100% respectively.  However, the FXR-target gene SHP in liver 
was not decreased.  In contrast, the ileum Fgf15 mRNA expression was significantly 
decreased.  Feeding the resin did not alter the BA uptake transporters on the 
sinusoidal membrane nor did it altered the efflux transporters on the canalicular 
membrane, however, the efflux transporters on the sinusoidal membrane of 
hepatocytes, Mrp3 and 4, were increased by the resin 22 and 150% respectively. 
The increased Mrp3 and 4 might be responsible for the increased serum BA 
concentration. 
In conclusion, the diminished FXR-Fgf15 signaling after resin-feeding is 
responsible for the decreased mRNA expression of Cyp7a1 and Cyp8b1.  The 
altered liver BA composition is likely responsible for the increased expression of 
Mrp3 and 4, which may contribute to the increased serum BA concentration. 
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6.4  Significance of the studies 
Knowing the non-hepatotoxic dose of each BA is critical in studying BA 
physiological or pharmacological functions.  Data generated by feeding mice a non-
hepatotoxic, rather than a hepatotoxic dose of individual BA, will provide more 
certainty in clarifying the signaling function of that BA, because there is no toxic 
effects which might obscure the BA functions. 
The novel concept brought out in my dissertation that the altered liver BA 
composition without an increase in the total liver BA concentration causes 
hepatotoxicity and can trigger BA receptor FXR mediated signaling pathway will lead 
to a new direction in BA research field and also will provide a new theory for drug 
discovery.   
Another exciting finding in my dissertation is that the resin can increase 
serum BA (total CA) concentration.  This finding will provide a new perspective for 
the understanding of the mechanism by which the resin lowers the serum glucose 
level in type 2 diabetes patients.  In addition, the altered BA composition after resin 
feeding resulted in an increased expression of the BA efflux transporter Mrp3 and 4 
which might be the reason why the serum BA concentration is increased.  
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Suppliers 
Chemicals 
Sigma Aldrich Chemical Company, St, Louis, MO: 
CA:   
Brand Name: Fluka  
Purity: ≥99.0%  
CDCA: 
Brand Name: Sigma 
Purity: ≥95%  
DCA:  
Brand Name: Fluka,  
Purity: ≥99.0% 
LCA:  
Brand Name: Sigma 
Purity: ≥97%  
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UDCA:  
Brand Name: Sigma 
Purity: ≥99% (Sigma) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
